

US011399722B2

(12) **United States Patent**
Al-Ali et al.

(10) **Patent No.:** **US 11,399,722 B2**
(45) **Date of Patent:** **Aug. 2, 2022**

(54) **PLETHYSMOGRAPHIC RESPIRATION RATE DETECTION**

(58) **Field of Classification Search**
CPC . A61B 5/14551; A61B 5/0816; A61B 5/0205; A61B 5/7246

(71) Applicant: **MASIMO CORPORATION**, Irvine, CA (US)

See application file for complete search history.

(72) Inventors: **Ammar Al-Ali**, San Juan Capistrano, CA (US); **Anmol Majmudar**, Irvine, CA (US)

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,682,161 A 8/1972 Alibert
4,109,643 A 8/1978 Bond et al.
(Continued)

(73) Assignee: **MASIMO CORPORATION**, Irvine, CA (US)

FOREIGN PATENT DOCUMENTS

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 565 days.

CA 2262236 4/2008
EP 0716628 12/1998
(Continued)

(21) Appl. No.: **16/119,215**

OTHER PUBLICATIONS

(22) Filed: **Aug. 31, 2018**

US 8,845,543 B2, 09/2014, Diab et al. (withdrawn)
(Continued)

(65) **Prior Publication Data**

US 2019/0076028 A1 Mar. 14, 2019

Primary Examiner — Christian Jang
Assistant Examiner — Karen E Toth
(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear, LLP

Related U.S. Application Data

(60) Continuation of application No. 15/095,912, filed on Apr. 11, 2016, now Pat. No. 10,098,550, which is a (Continued)


(57) **ABSTRACT**

A plethysmographic respiration processor is responsive to respiratory effects appearing on a blood volume waveform and the corresponding detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of respiration rate. A preprocessor identifies a windowed pleth corresponding to a physiologically acceptable series of plethysmograph waveform pulses. Multiple processors derive different parameters responsive to particular respiratory effects on the windowed pleth. Decision logic determines a respiration rate based upon at least a portion of these parameters.

(51) **Int. Cl.**
A61B 5/0205 (2006.01)
A61B 5/08 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC *A61B 5/0205* (2013.01); *A61B 5/02007* (2013.01); *A61B 5/029* (2013.01);
(Continued)

16 Claims, 17 Drawing Sheets



Related U.S. Application Data

- division of application No. 13/076,423, filed on Mar. 30, 2011, now Pat. No. 9,307,928.
- (60) Provisional application No. 61/364,141, filed on Jul. 14, 2010, provisional application No. 61/319,256, filed on Mar. 30, 2010.
- (51) **Int. Cl.**
A61B 5/026 (2006.01)
A61B 5/0295 (2006.01)
A61B 5/00 (2006.01)
G16H 15/00 (2018.01)
G16H 50/30 (2018.01)
G16H 50/00 (2018.01)
A61B 5/02 (2006.01)
A61B 5/029 (2006.01)
A61B 5/1455 (2006.01)
- (52) **U.S. Cl.**
 CPC *A61B 5/0261* (2013.01); *A61B 5/0295* (2013.01); *A61B 5/0816* (2013.01); *A61B 5/6826* (2013.01); *A61B 5/7203* (2013.01); *A61B 5/725* (2013.01); *A61B 5/7225* (2013.01); *A61B 5/7228* (2013.01); *A61B 5/7246* (2013.01); *A61B 5/7253* (2013.01); *A61B 5/7264* (2013.01); *A61B 5/7278* (2013.01); *A61B 5/742* (2013.01); *A61B 5/7405* (2013.01); *A61B 5/746* (2013.01); *A61B 5/7475* (2013.01); *G16H 15/00* (2018.01); *G16H 50/00* (2018.01); *G16H 50/30* (2018.01); *A61B 5/08* (2013.01); *A61B 5/0806* (2013.01); *A61B 5/14552* (2013.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,127,749 A	11/1978	Atoji et al.	5,448,996 A	9/1995	Bellin et al.
4,326,143 A	4/1982	Guth et al.	5,452,717 A	9/1995	Branigan et al.
4,507,653 A	3/1985	Bayer	D363,120 S	10/1995	Savage et al.
4,537,200 A	8/1985	Widrow	5,456,252 A	10/1995	Vari et al.
4,685,140 A	8/1987	Mount, II	5,479,934 A	1/1996	Imran
4,714,341 A	12/1987	Hamaguri	5,482,036 A	1/1996	Diab et al.
4,848,901 A	7/1989	Hood, Jr.	5,490,505 A	2/1996	Diab et al.
4,867,165 A	9/1989	Noller et al.	5,494,043 A	2/1996	O'Sullivan et al.
4,884,809 A	12/1989	Rowan	5,533,511 A	7/1996	Kaspari et al.
4,958,638 A	9/1990	Sharpe et al.	5,534,851 A	7/1996	Russek
4,960,128 A	10/1990	Gordon et al.	5,553,615 A	9/1996	Carim et al.
4,964,408 A	10/1990	Hink et al.	5,561,275 A	10/1996	Savage et al.
5,033,032 A	7/1991	Houghtaling	5,562,002 A	10/1996	Lalin
5,041,187 A	8/1991	Hink et al.	5,590,649 A	1/1997	Caro et al.
5,069,213 A	12/1991	Polczynski	5,602,924 A	2/1997	Durand et al.
5,111,817 A	5/1992	Clark et al.	5,613,496 A	3/1997	Arand et al.
5,119,814 A	6/1992	Minnich	5,632,272 A	5/1997	Diab et al.
5,143,078 A	9/1992	Mather et al.	5,638,403 A	6/1997	Birchler et al.
5,163,438 A	11/1992	Gordon et al.	5,638,816 A	6/1997	Kiani-Azarbayjany et al.
5,273,036 A	12/1993	Kronberg et al.	5,638,818 A	6/1997	Diab et al.
5,277,181 A	1/1994	Mendelson et al.	5,645,440 A	7/1997	Tobler et al.
5,309,922 A	5/1994	Schechter et al.	5,671,191 A	9/1997	Gerdt
5,319,355 A	6/1994	Russek	5,671,914 A	9/1997	Kalkhoran et al.
5,337,744 A	8/1994	Branigan	5,685,299 A	11/1997	Diab et al.
5,341,805 A	8/1994	Stavridi et al.	5,724,983 A	3/1998	Selker et al.
5,353,798 A	10/1994	Sieben	5,726,440 A	3/1998	Kalkhoran et al.
D353,195 S	12/1994	Savage et al.	D393,830 S	4/1998	Tobler et al.
D353,196 S	12/1994	Savage et al.	5,743,262 A	4/1998	Lepper, Jr. et al.
5,377,302 A	12/1994	Tsiang	5,747,806 A	5/1998	Khalil et al.
5,377,676 A	1/1995	Vari et al.	5,750,994 A	5/1998	Schlager
D359,546 S	6/1995	Savage et al.	5,758,644 A	6/1998	Diab et al.
5,431,170 A	7/1995	Mathews	5,760,910 A	6/1998	Lepper, Jr. et al.
5,436,499 A	7/1995	Namavar et al.	5,766,127 A	6/1998	Pologe et al.
D361,840 S	8/1995	Savage et al.	5,769,785 A	6/1998	Diab et al.
D362,063 S	9/1995	Savage et al.	5,782,757 A	7/1998	Diab et al.
			5,785,659 A	7/1998	Caro et al.
			5,791,347 A	8/1998	Flaherty et al.
			5,810,734 A	9/1998	Caro et al.
			5,819,007 A	10/1998	Elghazzawi
			5,823,950 A	10/1998	Diab et al.
			5,830,131 A	11/1998	Caro et al.
			5,833,618 A	11/1998	Caro et al.
			5,860,919 A	1/1999	Kiani-Azarbayjany et al.
			5,862,805 A	1/1999	Nitzan
			5,865,736 A	2/1999	Baker, Jr. et al.
			5,890,929 A	4/1999	Mills et al.
			5,904,654 A	5/1999	Wohltmann et al.
			5,919,134 A	7/1999	Diab
			5,928,156 A	7/1999	Krumbiegel
			5,934,925 A	8/1999	Tobler et al.
			5,940,182 A	8/1999	Lepper, Jr. et al.
			5,984,893 A	11/1999	Ward
			5,987,343 A	11/1999	Kinast
			5,995,855 A	11/1999	Kiani et al.
			5,997,343 A	12/1999	Mills et al.
			6,002,952 A	12/1999	Diab et al.
			6,010,937 A	1/2000	Karam et al.
			6,011,986 A	1/2000	Diab et al.
			6,027,452 A	2/2000	Flaherty et al.
			6,029,665 A	2/2000	Berthon-Jones
			6,036,642 A	3/2000	Diab et al.
			6,040,578 A	3/2000	Malin et al.
			6,045,509 A	4/2000	Caro et al.
			6,064,910 A	5/2000	Andersson et al.
			6,066,204 A	5/2000	Haven
			6,067,462 A	5/2000	Diab et al.
			6,081,735 A	6/2000	Diab et al.
			6,083,172 A	7/2000	Baker et al.
			6,088,607 A	7/2000	Diab et al.
			6,091,973 A	7/2000	Colla et al.
			6,110,522 A	8/2000	Lepper, Jr. et al.
			6,112,171 A	8/2000	Sugiyama et al.
			6,115,673 A	9/2000	Malin et al.
			6,124,597 A	9/2000	Shehada
			6,128,521 A	10/2000	Marro et al.
			6,129,675 A	10/2000	Jay
			6,138,675 A	10/2000	Berthon-Jones
			6,139,505 A	10/2000	Murphy
			6,144,868 A	11/2000	Parker

(56)

References Cited

U.S. PATENT DOCUMENTS

6,151,516 A	11/2000	Kiani-Azarbayjany et al.	6,643,530 B2	11/2003	Diab et al.
6,152,754 A	11/2000	Gerhardt et al.	6,647,280 B2	11/2003	Bahr et al.
6,157,850 A	12/2000	Diab et al.	6,650,917 B2	11/2003	Diab et al.
6,165,005 A	12/2000	Mills et al.	6,654,624 B2	11/2003	Diab et al.
6,165,151 A	12/2000	Weiner	6,658,276 B2	12/2003	Kiani et al.
6,168,568 B1	1/2001	Gavriely	6,659,960 B2	12/2003	Derksen et al.
6,178,343 B1	1/2001	Bindszus et al.	6,661,161 B1	12/2003	Lanzo et al.
6,184,521 B1	2/2001	Coffin, IV et al.	6,671,531 B2	12/2003	Al-Ali et al.
6,206,830 B1	3/2001	Diab et al.	6,678,543 B2	1/2004	Diab et al.
6,229,856 B1	5/2001	Diab et al.	6,684,090 B2	1/2004	Ali et al.
6,232,609 B1	5/2001	Snyder et al.	6,684,091 B2	1/2004	Parker
6,236,872 B1	5/2001	Diab et al.	6,697,656 B1	2/2004	Al-Ali
6,241,683 B1	6/2001	Macklem et al.	6,697,657 B1	2/2004	Shehada et al.
6,248,083 B1	6/2001	Smith et al.	6,697,658 B2	2/2004	Al-Ali
6,253,097 B1	6/2001	Aronow et al.	RE38,476 E	3/2004	Diab et al.
6,254,551 B1	7/2001	Varis	6,699,194 B1	3/2004	Diab et al.
6,255,708 B1	7/2001	Sudharsanan et al.	6,709,402 B2	3/2004	Dekker
6,256,523 B1	7/2001	Diab et al.	6,714,804 B2	3/2004	Al-Ali et al.
6,261,238 B1	7/2001	Gavriely	RE38,492 E	4/2004	Diab et al.
6,263,222 B1	7/2001	Diab et al.	6,721,582 B2	4/2004	Trepagnier et al.
6,278,522 B1	8/2001	Lepper, Jr. et al.	6,721,585 B1	4/2004	Parker
6,280,213 B1	8/2001	Tobler et al.	6,725,074 B1	4/2004	Kastle
6,280,381 B1	8/2001	Malin et al.	6,725,075 B2	4/2004	Al-Ali
6,285,896 B1	9/2001	Tobler et al.	6,728,560 B2	4/2004	Kollias et al.
6,301,493 B1	10/2001	Marro et al.	6,735,459 B2	5/2004	Parker
6,308,089 B1	10/2001	von der Ruhr et al.	6,738,652 B2	5/2004	Mattu et al.
6,317,627 B1	11/2001	Ennen et al.	6,745,060 B2	6/2004	Diab et al.
6,321,100 B1	11/2001	Parker	6,754,516 B2	6/2004	Mannheimer
6,325,761 B1	12/2001	Jay	6,760,607 B2	7/2004	Al-Ali
6,331,162 B1	12/2001	Mitchell	6,766,038 B1	7/2004	Sakuma et al.
6,334,065 B1	12/2001	Al-Ali et al.	6,770,028 B1	8/2004	Ali et al.
6,343,224 B1	1/2002	Parker	6,771,994 B2	8/2004	Kiani et al.
6,349,228 B1	2/2002	Kiani et al.	6,788,965 B2	9/2004	Ruchti et al.
6,360,114 B1	3/2002	Diab et al.	6,792,300 B1	9/2004	Diab et al.
6,361,501 B1	3/2002	Amano et al.	6,813,511 B2	11/2004	Diab et al.
6,368,283 B1	4/2002	Xu et al.	6,816,241 B2	11/2004	Grubisic
6,371,921 B1	4/2002	Caro et al.	6,816,741 B2	11/2004	Diab
6,377,829 B1	4/2002	Al-Ali	6,822,564 B2	11/2004	Al-Ali
6,383,143 B1	5/2002	Rost	6,826,419 B2	11/2004	Diab et al.
6,385,471 B1	5/2002	Mortz	6,830,711 B2	12/2004	Mills et al.
6,388,240 B2	5/2002	Schulz et al.	6,839,581 B1	1/2005	El-Solh et al.
6,397,091 B2	5/2002	Diab et al.	6,850,787 B2	2/2005	Weber et al.
6,411,373 B1	6/2002	Garside et al.	6,850,788 B2	2/2005	Al-Ali
6,415,167 B1	7/2002	Blank et al.	6,852,083 B2	2/2005	Caro et al.
6,430,437 B1	8/2002	Marro	6,861,639 B2	3/2005	Al-Ali
6,430,525 B1	8/2002	Weber et al.	6,869,402 B2	3/2005	Arnold
6,443,907 B1	9/2002	Mansy et al.	6,876,931 B2	4/2005	Lorenz et al.
6,463,311 B1	10/2002	Diab	6,898,452 B2	5/2005	Al-Ali et al.
6,470,199 B1	10/2002	Kopotic et al.	6,920,345 B2	7/2005	Al-Ali et al.
6,486,588 B2	11/2002	Doron et al.	6,931,268 B1	8/2005	Kiani-Azarbayjany et al.
6,487,429 B2	11/2002	Hockersmith et al.	6,934,570 B2	8/2005	Kiani et al.
6,491,647 B1	12/2002	Bridger et al.	6,939,305 B2	9/2005	Flaherty et al.
6,501,975 B2	12/2002	Diab et al.	6,943,348 B1	9/2005	Coffin IV
6,505,059 B1	1/2003	Kollias et al.	6,950,687 B2	9/2005	Al-Ali
6,515,273 B2	2/2003	Al-Ali	6,956,649 B2	10/2005	Acosta et al.
6,517,497 B2	2/2003	Rymut et al.	6,961,598 B2	11/2005	Diab
6,519,487 B1	2/2003	Parker	6,970,792 B1	11/2005	Diab
6,525,386 B1	2/2003	Mills et al.	6,979,812 B2	12/2005	Al-Ali
6,526,300 B1	2/2003	Kiani et al.	6,985,764 B2	1/2006	Mason et al.
6,534,012 B1	3/2003	Hazen et al.	6,990,364 B2	1/2006	Ruchti et al.
6,541,756 B2	4/2003	Schulz et al.	6,993,371 B2	1/2006	Kiani et al.
6,542,764 B1	4/2003	Al-Ali et al.	6,996,427 B2	2/2006	Ali et al.
6,580,086 B1	6/2003	Schulz et al.	6,998,247 B2	2/2006	Monfre et al.
6,584,336 B1	6/2003	Ali et al.	6,999,904 B2	2/2006	Weber et al.
6,587,196 B1	7/2003	Stippick et al.	7,003,338 B2	2/2006	Weber et al.
6,587,199 B1	7/2003	Luu	7,003,339 B2	2/2006	Diab et al.
6,595,316 B2	7/2003	Cybulski et al.	7,015,451 B2	3/2006	Dalke et al.
6,597,932 B2	7/2003	Tian et al.	7,024,233 B2	4/2006	Ali et al.
6,597,933 B2	7/2003	Kiani et al.	7,027,849 B2	4/2006	Al-Ali
6,606,511 B1	8/2003	Ali et al.	7,030,749 B2	4/2006	Al-Ali
6,632,181 B2	10/2003	Flaherty et al.	7,039,449 B2	5/2006	Al-Ali
6,635,559 B2	10/2003	Greenwald et al.	7,041,060 B2	5/2006	Flaherty et al.
6,639,668 B1	10/2003	Trepagnier	7,044,918 B2	5/2006	Diab
6,640,116 B2	10/2003	Diab	7,067,893 B2	6/2006	Mills et al.
6,640,117 B2	10/2003	Makarewicz et al.	D526,719 S	8/2006	Richie, Jr. et al.
			7,096,052 B2	8/2006	Mason et al.
			7,096,054 B2	8/2006	Abdul-Hafiz et al.
			7,096,060 B2	8/2006	Arand et al.
			D529,616 S	10/2006	Deros et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,132,641 B2	11/2006	Schulz et al.	7,563,110 B2	7/2009	Al-Ali et al.
7,133,710 B2	11/2006	Acosta et al.	7,593,230 B2	9/2009	Abul-Haj et al.
7,142,901 B2	11/2006	Kiani et al.	7,596,398 B2	9/2009	Al-Ali et al.
7,149,561 B2	12/2006	Diab	7,606,608 B2	10/2009	Blank et al.
7,186,966 B2	3/2007	Al-Ali	7,618,375 B2	11/2009	Flaherty
7,190,261 B2	3/2007	Al-Ali	7,620,674 B2	11/2009	Ruchti et al.
7,194,306 B1	3/2007	Turcott	D606,659 S	12/2009	Kiani et al.
7,215,984 B2	5/2007	Diab	7,629,039 B2	12/2009	Eckerbom et al.
7,215,986 B2	5/2007	Diab	7,640,140 B2	12/2009	Ruchti et al.
7,221,971 B2	5/2007	Diab	7,647,083 B2	1/2010	Al-Ali et al.
7,225,006 B2	5/2007	Al-Ali et al.	D609,193 S	2/2010	Al-Ali et al.
7,225,007 B2	5/2007	Al-Ali	D614,305 S	4/2010	Al-Ali et al.
RE39,672 E	6/2007	Shehada et al.	7,690,378 B1	4/2010	Turcott
7,239,905 B2	7/2007	Kiani-Azarbayjany et al.	7,697,966 B2	4/2010	Monfre et al.
7,245,953 B1	7/2007	Parker	7,698,105 B2	4/2010	Ruchti et al.
7,254,429 B2	8/2007	Schurman et al.	RE41,317 E	5/2010	Parker
7,254,431 B2	8/2007	Al-Ali	RE41,333 E	5/2010	Blank et al.
7,254,433 B2	8/2007	Diab et al.	7,729,733 B2	6/2010	Al-Ali et al.
7,254,434 B2	8/2007	Schulz et al.	7,734,320 B2	6/2010	Al-Ali
7,267,652 B2	9/2007	Coyle et al.	7,761,127 B2	7/2010	Al-Ali et al.
7,272,425 B2	9/2007	Al-Ali	7,761,128 B2	7/2010	Al-Ali et al.
7,274,955 B2	9/2007	Kiani et al.	7,764,982 B2	7/2010	Dalke et al.
D554,263 S	10/2007	Al-Ali	D621,516 S	8/2010	Kiani et al.
7,280,858 B2	10/2007	Al-Ali et al.	7,791,155 B2	9/2010	Diab
7,289,835 B2	10/2007	Mansfield et al.	7,801,581 B2	9/2010	Diab
7,292,883 B2	11/2007	De Felice et al.	7,822,452 B2	10/2010	Schurman et al.
7,295,866 B2	11/2007	Al-Ali	RE41,912 E	11/2010	Parker
7,328,053 B1	2/2008	Diab et al.	7,844,313 B2	11/2010	Kiani et al.
7,332,784 B2	2/2008	Mills et al.	7,844,314 B2	11/2010	Al-Ali
7,340,287 B2	3/2008	Mason et al.	7,844,315 B2	11/2010	Al-Ali
7,341,559 B2	3/2008	Schulz et al.	7,865,222 B2	1/2011	Weber et al.
7,343,186 B2	3/2008	Lamego et al.	7,873,497 B2	1/2011	Weber et al.
D566,282 S	4/2008	Al-Ali et al.	7,880,606 B2	2/2011	Al-Ali
7,355,512 B1	4/2008	Al-Ali	7,880,626 B2	2/2011	Al-Ali et al.
7,356,365 B2	4/2008	Schurman	7,891,355 B2	2/2011	Al-Ali et al.
7,361,146 B1	4/2008	Bharmi et al.	7,894,868 B2	2/2011	Al-Ali et al.
7,371,981 B2	5/2008	Abdul-Hafiz	7,899,507 B2	3/2011	Al-Ali et al.
7,373,193 B2	5/2008	Al-Ali et al.	7,899,518 B2	3/2011	Trepagnier et al.
7,373,194 B2	5/2008	Weber et al.	7,904,132 B2	3/2011	Weber et al.
7,376,453 B1	5/2008	Diab et al.	7,909,772 B2	3/2011	Popov et al.
7,377,794 B2	5/2008	Ali et al.	7,910,875 B2	3/2011	Al-Ali
7,377,899 B2	5/2008	Weber et al.	7,919,713 B2	4/2011	Al-Ali et al.
7,383,070 B2	6/2008	Diab et al.	7,937,128 B2	5/2011	Al-Ali
7,395,158 B2	7/2008	Monfre et al.	7,937,129 B2	5/2011	Mason et al.
7,398,115 B2	7/2008	Lynn	7,937,130 B2	5/2011	Diab et al.
7,403,806 B2	7/2008	Norris	7,941,199 B2	5/2011	Kiani
7,415,297 B2	8/2008	Al-Ali et al.	7,951,086 B2	5/2011	Flaherty et al.
7,428,432 B2	9/2008	Ali et al.	7,957,780 B2	6/2011	Lamego et al.
7,438,683 B2	10/2008	Al-Ali et al.	7,962,188 B2	6/2011	Kiani et al.
7,440,787 B2	10/2008	Diab	7,962,190 B1	6/2011	Diab et al.
7,454,240 B2	11/2008	Diab et al.	7,976,472 B2	7/2011	Kiani
7,467,002 B2	12/2008	Weber et al.	7,988,637 B2	8/2011	Diab
7,469,157 B2	12/2008	Diab et al.	7,990,382 B2	8/2011	Kiani
7,471,969 B2	12/2008	Diab et al.	7,991,446 B2	8/2011	Al-Ali et al.
7,471,971 B2	12/2008	Diab et al.	8,000,761 B2	8/2011	Al-Ali
7,483,729 B2	1/2009	Al-Ali et al.	8,008,088 B2	8/2011	Bellott et al.
7,483,730 B2	1/2009	Diab et al.	RE42,753 E	9/2011	Kiani-Azarbayjany et al.
7,489,958 B2	2/2009	Diab et al.	8,019,400 B2	9/2011	Diab et al.
7,496,391 B2	2/2009	Diab et al.	8,028,701 B2	10/2011	Al-Ali et al.
7,496,393 B2	2/2009	Diab et al.	8,029,765 B2	10/2011	Bellott et al.
D587,657 S	3/2009	Al-Ali et al.	8,036,727 B2	10/2011	Schurman et al.
7,499,741 B2	3/2009	Diab et al.	8,036,728 B2	10/2011	Diab et al.
7,499,835 B2	3/2009	Weber et al.	8,046,040 B2	10/2011	Ali et al.
7,500,950 B2	3/2009	Al-Ali et al.	8,046,041 B2	10/2011	Diab et al.
7,509,154 B2	3/2009	Diab et al.	8,046,042 B2	10/2011	Diab et al.
7,509,494 B2	3/2009	Al-Ali	8,048,040 B2	11/2011	Kiani
7,510,849 B2	3/2009	Schurman et al.	8,050,728 B2	11/2011	Al-Ali et al.
7,514,725 B2	4/2009	Wojtczuk et al.	RE43,169 E	2/2012	Parker
7,519,406 B2	4/2009	Blank et al.	8,118,620 B2	2/2012	Al-Ali et al.
7,526,328 B2	4/2009	Diab et al.	8,126,528 B2	2/2012	Diab et al.
D592,507 S	5/2009	Wachman et al.	8,128,572 B2	3/2012	Diab et al.
7,530,942 B1	5/2009	Diab	8,130,105 B2	3/2012	Al-Ali et al.
7,530,949 B2	5/2009	Al Ali et al.	8,145,287 B2	3/2012	Diab et al.
7,530,955 B2	5/2009	Diab et al.	8,150,487 B2	4/2012	Diab et al.
7,539,533 B2	5/2009	Tran	8,175,672 B2	5/2012	Parker
			8,180,420 B2	5/2012	Diab et al.
			8,182,443 B1	5/2012	Kiani
			8,185,180 B2	5/2012	Diab et al.
			8,190,223 B2	5/2012	Al-Ali et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

8,190,227 B2	5/2012	Diab et al.	8,581,732 B2	11/2013	Al-Ali et al.
8,203,438 B2	6/2012	Kiani et al.	8,588,880 B2	11/2013	Abdul-Hafiz et al.
8,203,704 B2	6/2012	Merritt et al.	8,597,274 B2	12/2013	Sloan
8,204,566 B2	6/2012	Schurman et al.	8,600,467 B2	12/2013	Al-Ali et al.
8,219,172 B2	7/2012	Schurman et al.	8,606,342 B2	12/2013	Diab
8,224,411 B2	7/2012	Al-Ali et al.	8,622,902 B2	1/2014	Woehrle
8,228,181 B2	7/2012	Al-Ali	8,626,255 B2	1/2014	Al-Ali et al.
8,229,532 B2	7/2012	Davis	8,630,691 B2	1/2014	Lamego et al.
8,229,533 B2	7/2012	Diab et al.	8,634,889 B2	1/2014	Al-Ali et al.
8,233,955 B2	7/2012	Al-Ali et al.	8,641,631 B2	2/2014	Sierra et al.
8,244,325 B2	8/2012	Al-Ali et al.	8,652,060 B2	2/2014	Al-Ali
8,255,026 B1	8/2012	Al-Ali	8,663,107 B2	3/2014	Kiani
8,255,027 B2	8/2012	Al-Ali et al.	8,666,468 B1	3/2014	Al-Ali
8,255,028 B2	8/2012	Al-Ali et al.	8,667,967 B2	3/2014	Al-Ali et al.
8,260,577 B2	9/2012	Weber et al.	8,670,811 B2	3/2014	O'Reilly
8,265,723 B1	9/2012	McHale et al.	8,670,814 B2	3/2014	Diab et al.
8,274,360 B2	9/2012	Sampath et al.	8,676,286 B2	3/2014	Weber et al.
8,280,473 B2	10/2012	Al-Ali	8,682,407 B2	3/2014	Al-Ali
8,301,217 B2	10/2012	Al-Ali et al.	RE44,823 E	4/2014	Parker
8,306,596 B2	11/2012	Schurman et al.	RE44,875 E	4/2014	Kiani et al.
8,310,336 B2	11/2012	Muhsin et al.	8,688,183 B2	4/2014	Bruinsma et al.
8,315,683 B2	11/2012	Al-Ali et al.	8,690,799 B2	4/2014	Telfort et al.
RE43,860 E	12/2012	Parker	8,700,112 B2	4/2014	Kiani
8,337,403 B2	12/2012	Al-Ali et al.	8,702,627 B2	4/2014	Telfort et al.
8,346,330 B2	1/2013	Lamego	8,706,179 B2	4/2014	Parker
8,353,842 B2	1/2013	Al-Ali et al.	8,712,494 B1	4/2014	MacNeish, III et al.
8,355,766 B2	1/2013	MacNeish, III et al.	8,715,206 B2	5/2014	Telfort et al.
8,359,080 B2	1/2013	Diab et al.	8,718,735 B2	5/2014	Lamego et al.
8,364,223 B2	1/2013	Al-Ali et al.	8,718,737 B2	5/2014	Diab et al.
8,364,226 B2	1/2013	Diab et al.	8,718,738 B2	5/2014	Blank et al.
8,374,665 B2	2/2013	Lamego	8,720,249 B2	5/2014	Al-Ali
8,385,995 B2	2/2013	Al-Ali et al.	8,721,541 B2	5/2014	Al-Ali et al.
8,385,996 B2	2/2013	Smith et al.	8,721,542 B2	5/2014	Al-Ali et al.
8,388,353 B2	3/2013	Kiani et al.	8,723,677 B1	5/2014	Kiani
8,399,822 B2	3/2013	Al-Ali	8,740,792 B1	6/2014	Kiani et al.
8,401,602 B2	3/2013	Kiani	8,754,776 B2	6/2014	Poeze et al.
8,405,608 B2	3/2013	Al-Ali et al.	8,755,535 B2	6/2014	Telfort et al.
8,414,499 B2	4/2013	Al-Ali et al.	8,755,856 B2	6/2014	Diab et al.
8,418,524 B2	4/2013	Al-Ali	8,755,872 B1	6/2014	Marinow
8,423,106 B2	4/2013	Lamego et al.	8,761,850 B2	6/2014	Lamego
8,428,967 B2	4/2013	Olsen et al.	8,764,671 B2	7/2014	Kiani
8,430,817 B1	4/2013	Al-Ali et al.	8,768,423 B2	7/2014	Shakespeare et al.
8,437,825 B2	5/2013	Dalvi et al.	8,771,204 B2	7/2014	Telfort et al.
8,455,290 B2	6/2013	Siskavich	8,777,634 B2	7/2014	Kiani et al.
8,457,703 B2	6/2013	Al-Ali	8,781,543 B2	7/2014	Diab et al.
8,457,707 B2	6/2013	Kiani	8,781,544 B2	7/2014	Al-Ali et al.
8,463,349 B2	6/2013	Diab et al.	8,781,549 B2	7/2014	Al-Ali et al.
8,466,286 B2	6/2013	Bellot et al.	8,788,003 B2	7/2014	Schurman et al.
8,471,713 B2	6/2013	Poeze et al.	8,790,268 B2	7/2014	Al-Ali
8,473,020 B2	6/2013	Kiani et al.	8,792,949 B2	7/2014	Baker
8,478,538 B2	7/2013	McGonigle et al.	8,801,613 B2	8/2014	Al-Ali et al.
8,483,787 B2	7/2013	Al-Ali et al.	8,821,397 B2	9/2014	Al-Ali et al.
8,489,364 B2	7/2013	Weber et al.	8,821,415 B2	9/2014	Al-Ali et al.
8,498,684 B2	7/2013	Weber et al.	8,830,449 B1	9/2014	Lamego et al.
8,504,128 B2	8/2013	Blank et al.	8,831,700 B2	9/2014	Schurman et al.
8,509,867 B2	8/2013	Workman et al.	8,840,549 B2	9/2014	Al-Ali et al.
8,515,509 B2	8/2013	Bruinsma et al.	8,847,740 B2	9/2014	Kiani et al.
8,523,781 B2	9/2013	Al-Ali	8,849,365 B2	9/2014	Smith et al.
8,529,301 B2	9/2013	Al-Ali et al.	8,852,094 B2	10/2014	Al-Ali et al.
8,532,727 B2	9/2013	Ali et al.	8,852,994 B2	10/2014	Wojtczuk et al.
8,532,728 B2	9/2013	Diab et al.	8,868,147 B2	10/2014	Stippick et al.
D692,145 S	10/2013	Al-Ali et al.	8,868,150 B2	10/2014	Al-Ali et al.
8,547,209 B2	10/2013	Kiani et al.	8,870,792 B2	10/2014	Al-Ali et al.
8,548,548 B2	10/2013	Al-Ali	8,886,271 B2	11/2014	Kiani et al.
8,548,549 B2	10/2013	Schurman et al.	8,888,539 B2	11/2014	Al-Ali et al.
8,548,550 B2	10/2013	Al-Ali et al.	8,888,708 B2	11/2014	Diab et al.
8,560,032 B2	10/2013	Al-Ali et al.	8,892,180 B2	11/2014	Weber et al.
8,560,034 B1	10/2013	Diab et al.	8,897,847 B2	11/2014	Al-Ali
8,570,167 B2	10/2013	Al-Ali	8,909,310 B2	12/2014	Lamego
8,570,503 B2	10/2013	Vo et al.	8,911,377 B2	12/2014	Al-Ali
8,571,617 B2	10/2013	Reichgott et al.	8,912,909 B2	12/2014	Al-Ali et al.
8,571,618 B1	10/2013	Lamego et al.	8,920,317 B2	12/2014	Al-Ali et al.
8,571,619 B2	10/2013	Al-Ali et al.	8,921,699 B2	12/2014	Al-Ali et al.
8,584,345 B2	10/2013	Al-Ali et al.	8,922,382 B2	12/2014	Al-Ali et al.
8,577,431 B2	11/2013	Lamego et al.	8,929,964 B2	1/2015	Al-Ali et al.
			8,942,777 B2	1/2015	Diab et al.
			8,948,834 B2	2/2015	Diab et al.
			8,948,835 B2	2/2015	Diab
			8,965,471 B2	2/2015	Lamego

(56)

References Cited

U.S. PATENT DOCUMENTS

8,983,564 B2	3/2015	Al-Ali	9,474,474 B2	10/2016	Lamego et al.
8,989,831 B2	3/2015	Al-Ali et al.	9,480,422 B2	11/2016	Al-Ali
8,996,085 B2	3/2015	Kiani et al.	9,480,435 B2	11/2016	Olsen
8,998,809 B2	4/2015	Kiani	9,492,110 B2	11/2016	Al-Ali et al.
9,028,429 B2	5/2015	Telfort et al.	9,510,779 B2	12/2016	Poeze et al.
9,037,207 B2	5/2015	Al-Ali et al.	9,517,024 B2	12/2016	Kiani et al.
9,060,721 B2	6/2015	Reichgott et al.	9,532,722 B2	1/2017	Lamego et al.
9,066,666 B2	6/2015	Kiani	9,538,949 B2	1/2017	Al-Ali et al.
9,066,680 B1	6/2015	Al-Ali et al.	9,538,980 B2	1/2017	Telfort et al.
9,072,474 B2	7/2015	Al-Ali et al.	9,549,696 B2	1/2017	Lamego et al.
9,078,560 B2	7/2015	Schurman et al.	9,554,737 B2	1/2017	Schurman et al.
9,084,569 B2	7/2015	Weber et al.	9,560,996 B2	2/2017	Kiani
9,095,316 B2	8/2015	Welch et al.	9,560,998 B2	2/2017	Al-Ali et al.
9,106,038 B2	8/2015	Telfort et al.	9,566,019 B2	2/2017	Al-Ali et al.
9,107,625 B2	8/2015	Telfort et al.	9,579,039 B2	2/2017	Jansen et al.
9,107,626 B2	8/2015	Al-Ali et al.	9,591,975 B2	3/2017	Dalvi et al.
9,113,831 B2	8/2015	Al-Ali	9,622,692 B2	4/2017	Lamego et al.
9,113,832 B2	8/2015	Al-Ali	9,622,693 B2	4/2017	Diab
9,119,595 B2	9/2015	Lamego	D788,312 S	5/2017	Al-Ali et al.
9,131,881 B2	9/2015	Diab et al.	9,649,054 B2	5/2017	Lamego et al.
9,131,882 B2	9/2015	Al-Ali et al.	9,659,475 B2	5/2017	Kaib
9,131,883 B2	9/2015	Al-Ali	9,697,928 B2	7/2017	Al-Ali et al.
9,131,917 B2	9/2015	Telfort et al.	9,717,458 B2	8/2017	Lamego et al.
9,135,398 B2	9/2015	Kaib	9,724,016 B1	8/2017	Al-Ali et al.
9,138,180 B1	9/2015	Coverston et al.	9,724,024 B2	8/2017	Al-Ali
9,138,182 B2	9/2015	Al-Ali et al.	9,724,025 B1	8/2017	Kiani et al.
9,138,192 B2	9/2015	Weber et al.	9,749,232 B2	8/2017	Sampath et al.
9,142,117 B2	9/2015	Muhsin et al.	9,750,442 B2	9/2017	Olsen
9,153,112 B1	10/2015	Kiani et al.	9,750,461 B1	9/2017	Telfort
9,153,121 B2	10/2015	Kiani et al.	9,775,545 B2	10/2017	Al-Ali et al.
9,161,696 B2	10/2015	Al-Ali et al.	9,778,079 B1	10/2017	Al-Ali et al.
9,161,713 B2	10/2015	Al-Ali et al.	9,782,077 B2	10/2017	Lamego et al.
9,167,995 B2	10/2015	Lamego et al.	9,787,568 B2	10/2017	Lamego et al.
9,176,141 B2	11/2015	Al-Ali et al.	9,808,188 B1	11/2017	Perea et al.
9,186,102 B2	11/2015	Bruinsma et al.	9,839,379 B2	12/2017	Al-Ali et al.
9,192,312 B2	11/2015	Al-Ali	9,839,381 B1	12/2017	Weber et al.
9,192,329 B2	11/2015	Al-Ali	9,847,749 B2	12/2017	Kiani et al.
9,192,351 B1	11/2015	Telfort et al.	9,848,800 B1	12/2017	Lee
9,195,385 B2	11/2015	Al-Ali et al.	9,861,298 B2	1/2018	Eckerbom et al.
9,211,072 B2	12/2015	Kiani	9,861,305 B1	1/2018	Weber et al.
9,211,095 B1	12/2015	Al-Ali	9,877,650 B2	1/2018	Muhsin et al.
9,218,454 B2	12/2015	Kiani et al.	9,891,079 B2	2/2018	Dalvi
9,220,440 B2	12/2015	Addison et al.	9,924,897 B1	3/2018	Abdul-Hafiz
9,226,696 B2	1/2016	Kiani	9,936,917 B2	4/2018	Poeze et al.
9,241,662 B2	1/2016	Al-Ali et al.	9,955,937 B2	5/2018	Telfort
9,245,668 B1	1/2016	Vo et al.	9,965,946 B2	5/2018	Al-Ali et al.
9,259,185 B2	1/2016	Abdul-Hafiz et al.	9,968,266 B2	5/2018	An et al.
9,267,572 B2	2/2016	Barker et al.	D820,865 S	6/2018	Muhsin et al.
9,277,880 B2	2/2016	Poeze et al.	9,986,952 B2	6/2018	Dalvi et al.
9,289,167 B2	3/2016	Diab et al.	D822,215 S	7/2018	Al-Ali et al.
9,295,421 B2	3/2016	Kiani et al.	D822,216 S	7/2018	Barker et al.
9,307,928 B1	4/2016	Al-Ali et al.	10,010,276 B2	7/2018	Al-Ali et al.
9,323,894 B2	4/2016	Kiani	10,086,138 B1	10/2018	Novak, Jr.
D755,392 S	5/2016	Hwang et al.	10,111,591 B2	10/2018	Dyell et al.
9,326,712 B1	5/2016	Kiani	D833,624 S	11/2018	DeJong et al.
9,333,316 B2	5/2016	Kiani	10,123,729 B2	11/2018	Dyell et al.
9,339,220 B2	5/2016	Lamego et al.	D835,282 S	12/2018	Barker et al.
9,341,565 B2	5/2016	Lamego et al.	D835,283 S	12/2018	Barker et al.
9,351,673 B2	5/2016	Diab et al.	D835,284 S	12/2018	Barker et al.
9,351,675 B2	5/2016	Al-Ali et al.	D835,285 S	12/2018	Barker et al.
9,364,181 B2	6/2016	Kiani et al.	10,149,616 B2	12/2018	Al-Ali et al.
9,368,671 B2	6/2016	Wojtczuk et al.	10,154,815 B2	12/2018	Al-Ali et al.
9,370,325 B2	6/2016	Al-Ali et al.	10,159,412 B2	12/2018	Lamego et al.
9,370,326 B2	6/2016	McHale et al.	10,188,348 B2	1/2019	Al-Ali et al.
9,370,335 B2	6/2016	Al-Ali et al.	RE47,218 E	2/2019	Al-Ali
9,375,185 B2	6/2016	Ali et al.	RE47,244 E	2/2019	Kiani et al.
9,378,637 B2	6/2016	Kaib	RE47,249 E	2/2019	Kiani et al.
9,386,953 B2	7/2016	Al-Ali	10,205,291 B2	2/2019	Scruggs et al.
9,386,961 B2	7/2016	Al-Ali et al.	10,226,187 B2	3/2019	Al-Ali et al.
9,392,945 B2	7/2016	Al-Ali et al.	10,231,657 B2	3/2019	Al-Ali et al.
9,397,448 B2	7/2016	Al-Ali et al.	10,231,670 B2	3/2019	Blank et al.
9,408,542 B1	8/2016	Kinast et al.	RE47,353 E	4/2019	Kiani et al.
9,436,645 B2	9/2016	Al-Ali et al.	10,279,247 B2	5/2019	Kiani
9,445,759 B1	9/2016	Lamego et al.	10,292,664 B2	5/2019	Al-Ali
9,466,919 B2	10/2016	Kiani et al.	10,299,720 B2	5/2019	Brown et al.
			10,327,337 B2	6/2019	Schmidt et al.
			10,327,713 B2	6/2019	Barker et al.
			10,332,630 B2	6/2019	Al-Ali
			10,383,520 B2	8/2019	Wojtczuk et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

10,383,527 B2	8/2019	Al-Ali	2003/0144582 A1	7/2003	Cohen et al.
10,388,120 B2	8/2019	Muhsin et al.	2003/0156288 A1	8/2003	Barnum et al.
D864,120 S	10/2019	Forrest et al.	2003/0158466 A1	8/2003	Lynn et al.
10,441,181 B1	10/2019	Telfort et al.	2003/0163033 A1	8/2003	Dekker et al.
10,441,196 B2	10/2019	Eckerbom et al.	2003/0163054 A1	8/2003	Dekker
10,448,844 B2	10/2019	Al-Ali et al.	2003/0212312 A1	11/2003	Coffin, IV et al.
10,448,871 B2	10/2019	Al-Ali et al.	2004/0010202 A1	1/2004	Nakatani
10,456,038 B2	10/2019	Lamego et al.	2004/0034293 A1	2/2004	Kimball
10,463,340 B2	11/2019	Telfort et al.	2004/0039273 A1	2/2004	Terry
10,471,159 B1	11/2019	Lapotko et al.	2004/0059203 A1	3/2004	Guerrero
10,505,311 B2	12/2019	Al-Ali et al.	2004/0060362 A1	4/2004	Kjellmann et al.
10,524,738 B2	1/2020	Olsen	2004/0087846 A1	5/2004	Wasserman
10,532,174 B2	1/2020	Al-Ali	2004/0106163 A1	6/2004	Workman, Jr. et al.
10,537,285 B2	1/2020	Shreim et al.	2004/0133087 A1	7/2004	Ali et al.
10,542,903 B2	1/2020	Al-Ali et al.	2004/0158162 A1	8/2004	Narimatsu
10,555,678 B2	2/2020	Dalvi et al.	2004/0225332 A1	11/2004	Gebhardt
10,568,553 B2	2/2020	O'Neil et al.	2004/0260186 A1	12/2004	Dekker
RE47,882 E	3/2020	Al-Ali	2005/0010166 A1	1/2005	Hickle
10,608,817 B2	3/2020	Haider et al.	2005/0027205 A1	2/2005	Tarassenko et al.
D880,477 S	4/2020	Forrest et al.	2005/0048456 A1	3/2005	Chefd'hotel et al.
10,617,302 B2	4/2020	Al-Ali et al.	2005/0055276 A1	3/2005	Kiani et al.
10,617,335 B2	4/2020	Al-Ali et al.	2005/0070774 A1	3/2005	Addison et al.
10,637,181 B2	4/2020	Al-Ali et al.	2005/0107699 A1	5/2005	Loftman
D887,548 S	6/2020	Abdul-Hafiz et al.	2005/0116820 A1	6/2005	Goldreich
D887,549 S	6/2020	Abdul-Hafiz et al.	2005/0177096 A1	8/2005	Bollish et al.
10,667,764 B2	6/2020	Ahmed et al.	2005/0199056 A1	9/2005	Strong
D890,708 S	7/2020	Forrest et al.	2005/0234317 A1	10/2005	Kiani
10,721,785 B2	7/2020	Al-Ali	2006/0047215 A1	3/2006	Newman et al.
10,736,518 B2	8/2020	Al-Ali et al.	2006/0073719 A1	4/2006	Kiani
10,750,984 B2	8/2020	Pauley et al.	2006/0129216 A1	6/2006	Hastings et al.
D897,098 S	9/2020	Al-Ali	2006/0149144 A1	7/2006	Lynn et al.
10,779,098 B2	9/2020	Iswanto et al.	2006/0155206 A1	7/2006	Lynn
10,827,961 B1	11/2020	Iyengar et al.	2006/0155207 A1	7/2006	Lynn et al.
10,828,007 B1	11/2020	Telfort et al.	2006/0161071 A1	7/2006	Lynn et al.
10,832,818 B2	11/2020	Muhsin et al.	2006/0189871 A1	8/2006	Al-Ali et al.
10,849,554 B2	12/2020	Shreim et al.	2006/0189880 A1	8/2006	Lynn et al.
10,856,750 B2	12/2020	Indorf et al.	2006/0195041 A1	8/2006	Lynn et al.
D906,970 S	1/2021	Forrest et al.	2006/0235324 A1	10/2006	Lynn
10,918,281 B2	2/2021	Al-Ali et al.	2006/0238333 A1	10/2006	Welch et al.
10,932,705 B2	3/2021	Muhsin et al.	2006/0241510 A1	10/2006	Halperin et al.
10,932,729 B2	3/2021	Kiani et al.	2006/0258921 A1	11/2006	Addison et al.
10,939,878 B2	3/2021	Kiani et al.	2007/0032732 A1	2/2007	Shelley et al.
D916,135 S	4/2021	Indorf et al.	2007/0055198 A1	3/2007	O'Mahony et al.
D917,550 S	4/2021	Indorf et al.	2007/0073116 A1	3/2007	Kiani et al.
D917,564 S	4/2021	Indorf et al.	2007/0093721 A1	4/2007	Lynn et al.
D917,704 S	4/2021	Al-Ali et al.	2007/0129643 A1	6/2007	Kwok et al.
10,987,066 B2	4/2021	Chandran et al.	2007/0129647 A1	6/2007	Lynn
10,991,135 B2	4/2021	Al-Ali et al.	2007/0135725 A1	6/2007	Hatlestad
D919,094 S	5/2021	Al-Ali et al.	2007/0149860 A1	6/2007	Lynn et al.
D919,100 S	5/2021	Al-Ali et al.	2007/0163353 A1	7/2007	Lee et al.
11,006,867 B2	5/2021	Al-Ali	2007/0180140 A1	8/2007	Welch et al.
D921,202 S	6/2021	Al-Ali et al.	2007/0185397 A1	8/2007	Govari et al.
11,024,064 B2	6/2021	Muhsin et al.	2007/0213619 A1	9/2007	Linder
11,026,604 B2	6/2021	Chen et al.	2007/0239057 A1	10/2007	Pu et al.
D925,597 S	7/2021	Chandran et al.	2007/0244377 A1	10/2007	Cozad et al.
D927,699 S	8/2021	Al-Ali et al.	2007/0282212 A1	12/2007	Sierra et al.
11,076,777 B2	8/2021	Lee et al.	2008/0013747 A1	1/2008	Tran
11,114,188 B2	9/2021	Poeze et al.	2008/0039735 A1	2/2008	Hickerson
D933,232 S	10/2021	Al-Ali et al.	2008/0064965 A1	3/2008	Jay et al.
11,145,408 B2	10/2021	Sampath et al.	2008/0067132 A1	3/2008	Ross et al.
11,147,518 B1	10/2021	Al-Ali et al.	2008/0071185 A1	3/2008	Beck et al.
11,185,262 B2	11/2021	Al-Ali et al.	2008/0076972 A1	3/2008	Dorogusker et al.
11,191,484 B2	12/2021	Kiani et al.	2008/0079299 A1	4/2008	Jackson
2001/0002206 A1	5/2001	Diab et al.	2008/0094228 A1	4/2008	Welch et al.
2001/0034477 A1	10/2001	Mansfield et al.	2008/0119716 A1	5/2008	Boric-Lubecke et al.
2001/0039483 A1	11/2001	Brand et al.	2008/0161878 A1	7/2008	Tehrani et al.
2002/0010401 A1	1/2002	Bushmakina et al.	2008/0167541 A1	7/2008	Takala et al.
2002/0058864 A1	5/2002	Mansfield et al.	2008/0177195 A1	7/2008	Armitstead
2002/0133080 A1	9/2002	Apruzzese et al.	2008/0188733 A1	8/2008	Al-Ali
2002/0193670 A1	12/2002	Garfield et al.	2008/0188760 A1	8/2008	Al-Ali
2003/0013975 A1	1/2003	Kiani	2008/0218153 A1	9/2008	Patel et al.
2003/0015368 A1	1/2003	Cybulski et al.	2008/0221418 A1	9/2008	Al-Ali et al.
2003/0018243 A1	1/2003	Gerhardt et al.	2008/0221512 A1	9/2008	Da Silva et al.
2003/0065269 A1	4/2003	Vetter	2008/0275349 A1	11/2008	Halperin et al.
2003/0076494 A1	4/2003	Bonin et al.	2008/0304580 A1	12/2008	Ichiyama
			2009/0018409 A1	1/2009	Banet et al.
			2009/0018429 A1	1/2009	Saliga et al.
			2009/0018453 A1	1/2009	Banet et al.
			2009/0036759 A1	2/2009	Ault et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2009/0043179	A1	2/2009	Melker et al.	2012/0330112	A1	12/2012	Lamego et al.
2009/0093687	A1	4/2009	Telfort et al.	2013/0023775	A1	1/2013	Lamego et al.
2009/0095926	A1	4/2009	MacNeish, III	2013/0045685	A1	2/2013	Kiani
2009/0112096	A1	4/2009	Tamura	2013/0046204	A1	2/2013	Lamego
2009/0160654	A1	6/2009	Yang	2013/0041591	A1	3/2013	Lamego
2009/0167332	A1	7/2009	Forbes	2013/0060147	A1	3/2013	Welch et al.
2009/0187065	A1	7/2009	Basinger	2013/0096405	A1	4/2013	Garfio
2009/0227882	A1	9/2009	Foo	2013/0096936	A1	4/2013	Sampath et al.
2009/0240119	A1	9/2009	Schwaibold et al.	2013/0109935	A1	5/2013	Al-Ali et al.
2009/0247848	A1	10/2009	Baker	2013/0116578	A1	5/2013	An et al.
2009/0247984	A1	10/2009	Lamego et al.	2013/0128690	A1	5/2013	Gopalan
2009/0275844	A1	11/2009	Al-Ali	2013/0137936	A1	5/2013	Baker, Jr. et al.
2009/0299157	A1	12/2009	Telfort et al.	2013/0162433	A1	6/2013	Muhsin et al.
2009/0312612	A1*	12/2009	Rantala A61B 5/0205 600/301	2013/0190581	A1	7/2013	Al-Ali et al.
2009/0326349	A1	12/2009	McGonigle et al.	2013/0190595	A1	7/2013	Oraevsky
2010/0004518	A1	1/2010	Vo et al.	2013/0197328	A1	8/2013	Diab et al.
2010/0004552	A1	1/2010	Zhang et al.	2013/0243021	A1	9/2013	Siskavich
2010/0014761	A1*	1/2010	Addison G06K 9/00516 382/207	2013/0253334	A1	9/2013	Al-Ali et al.
2010/0016682	A1	1/2010	Schluess et al.	2013/0274571	A1	10/2013	Diab et al.
2010/0016693	A1	1/2010	Addison	2013/0296672	A1	11/2013	Dalvi et al.
2010/0030040	A1	2/2010	Poeze et al.	2013/0296726	A1	11/2013	Nievauer et al.
2010/0099964	A1	4/2010	O'Reilly et al.	2013/0317370	A1	11/2013	Dalvi et al.
2010/0130873	A1	5/2010	Yuen	2013/0324808	A1	12/2013	Al-Ali et al.
2010/0204550	A1	8/2010	Heneghan	2013/0331670	A1	12/2013	Kiani
2010/0234718	A1	9/2010	Sampath et al.	2013/0338461	A1	12/2013	Lamego et al.
2010/0261979	A1	10/2010	Kiani	2013/0345921	A1	12/2013	Al-Ali et al.
2010/0270257	A1	10/2010	Wachman et al.	2014/0012100	A1	1/2014	Lamego et al.
2010/0274099	A1	10/2010	Telfort et al.	2014/0025306	A1	1/2014	Weber et al.
2010/0295686	A1	11/2010	Sloan	2014/0034353	A1	2/2014	Al-Ali et al.
2010/0298661	A1	11/2010	McCombie et al.	2014/0051953	A1	2/2014	Lamego et al.
2010/0298730	A1	11/2010	Taressenko et al.	2014/0058230	A1	2/2014	Abdul-Hafiz et al.
2010/0324377	A1	12/2010	Woehrle	2014/0066783	A1	3/2014	Kiani et al.
2010/0331903	A1	12/2010	Zhang	2014/0077956	A1	3/2014	Sampath et al.
2011/0001605	A1	1/2011	Kiani	2014/0081100	A1	3/2014	Muhsin et al.
2011/0009710	A1	1/2011	Kroeger et al.	2014/0081175	A1	3/2014	Telfort
2011/0028806	A1	2/2011	Merritt et al.	2014/0094667	A1	4/2014	Schurman et al.
2011/0028809	A1	2/2011	Goodman	2014/0100434	A1	4/2014	Diab et al.
2011/0040197	A1	2/2011	Welch et al.	2014/0114199	A1	4/2014	Lamego et al.
2011/0040713	A1	2/2011	Colman	2014/0120564	A1	5/2014	Workman et al.
2011/0066062	A1	3/2011	Banet et al.	2014/0121482	A1	5/2014	Merritt et al.
2011/0074409	A1	3/2011	Stoughton	2014/0121483	A1	5/2014	Kiani
2011/0082711	A1	4/2011	Poeze et al.	2014/0127137	A1	5/2014	Bellott et al.
2011/0087081	A1	4/2011	Kiani et al.	2014/0128696	A1	5/2014	Al-Ali
2011/0105854	A1	5/2011	Kiani et al.	2014/0128699	A1	5/2014	Al-Ali et al.
2011/0118561	A1	5/2011	Tari et al.	2014/0129702	A1	5/2014	Lamego et al.
2011/0118573	A1	5/2011	McKenna	2014/0135588	A1	5/2014	Al-Ali et al.
2011/0125060	A1	5/2011	Telfort et al.	2014/0142401	A1	5/2014	Al-Ali et al.
2011/0137297	A1	6/2011	Kiani et al.	2014/0142402	A1	5/2014	Al-Ali et al.
2011/0172498	A1	7/2011	Olsen et al.	2014/0163344	A1	6/2014	Al-Ali
2011/0172561	A1	7/2011	Kiani et al.	2014/0163402	A1	6/2014	Lamego et al.
2011/0208015	A1	8/2011	Welch et al.	2014/0166076	A1	6/2014	Kiani et al.
2011/0209915	A1	9/2011	Telfort et al.	2014/0171763	A1	6/2014	Diab
2011/0213212	A1	9/2011	Al-Ali	2014/0180038	A1	6/2014	Kiani et al.
2011/0222371	A1	9/2011	Liu et al.	2014/0180154	A1	6/2014	Sierra et al.
2011/0230733	A1	9/2011	Al-Ali et al.	2014/0180160	A1	6/2014	Brown et al.
2011/0237911	A1	9/2011	Lamego et al.	2014/0187973	A1	7/2014	Brown et al.
2012/0016255	A1	1/2012	Masuo	2014/0194709	A1	7/2014	Al-Ali et al.
2012/0059267	A1	3/2012	Lamego et al.	2014/0194711	A1	7/2014	Al-Ali
2012/0070013	A1	3/2012	Vau	2014/0194766	A1	7/2014	Al-Ali et al.
2012/0101344	A1	4/2012	Desjardins	2014/0206963	A1	7/2014	Diab et al.
2012/0116175	A1	5/2012	Al-Ali et al.	2014/0213864	A1	7/2014	Abdul-Hafiz et al.
2012/0123231	A1	5/2012	O'Reilly	2014/0243627	A1	8/2014	Diab et al.
2012/0165629	A1	6/2012	Merritt et al.	2014/0266790	A1	9/2014	Al-Ali et al.
2012/0179006	A1	7/2012	Jansen et al.	2014/0275808	A1	9/2014	Poeze et al.
2012/0209082	A1	8/2012	Al-Ali	2014/0275835	A1	9/2014	Lamego et al.
2012/0209084	A1	8/2012	Olsen et al.	2014/0275871	A1	9/2014	Lamego et al.
2012/0226117	A1	9/2012	Lamego et al.	2014/0275872	A1	9/2014	Merritt et al.
2012/0227739	A1	9/2012	Kiani	2014/0275881	A1	9/2014	Lamego et al.
2012/0253140	A1	10/2012	Addison et al.	2014/0288400	A1	9/2014	Diab et al.
2012/0262298	A1	10/2012	Bohm	2014/0296664	A1	10/2014	Bruinsma et al.
2012/0283524	A1	11/2012	Kiani et al.	2014/0303520	A1	10/2014	Telfort et al.
2012/0296178	A1	11/2012	Lamego et al.	2014/0309506	A1	10/2014	Lamego et al.
2012/0319816	A1	12/2012	Al-Ali	2014/0316217	A1	10/2014	Purdon et al.
				2014/0316218	A1	10/2014	Purdon et al.
				2014/0316228	A1	10/2014	Blank et al.
				2014/0323825	A1	10/2014	Al-Ali et al.
				2014/0323897	A1	10/2014	Brown et al.
				2014/0323898	A1	10/2014	Purdon et al.
				2014/0330092	A1	11/2014	Al-Ali et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2014/0330098 A1 11/2014 Merritt et al.
 2014/0330099 A1 11/2014 Al-Ali et al.
 2014/0333440 A1 11/2014 Kiani
 2014/0336481 A1 11/2014 Shakespeare et al.
 2014/0343436 A1 11/2014 Kiani
 2015/0005600 A1 1/2015 Blank et al.
 2015/0011907 A1 1/2015 Purdon et al.
 2015/0018650 A1 1/2015 Al-Ali et al.
 2015/0073241 A1 3/2015 Lamego
 2015/0080754 A1 3/2015 Purdon et al.
 2015/0099950 A1 4/2015 Al-Ali et al.
 2016/0196388 A1 7/2016 Lamego
 2016/0283665 A1 9/2016 Sampath et al.
 2016/0367173 A1 12/2016 Dalvi et al.
 2017/0024748 A1 1/2017 Haider
 2017/0042488 A1 2/2017 Muhsin
 2017/0173632 A1 6/2017 Al-Ali
 2017/0251974 A1 9/2017 Shreim et al.
 2017/0311891 A1 11/2017 Kiani et al.
 2018/0103874 A1 4/2018 Lee et al.
 2018/0242926 A1 8/2018 Muhsin et al.
 2018/0247353 A1 8/2018 Al-Ali et al.
 2018/0247712 A1 8/2018 Muhsin et al.
 2018/0256087 A1 9/2018 Al-Ali et al.
 2018/0296161 A1 10/2018 Shreim et al.
 2018/0300919 A1 10/2018 Muhsin et al.
 2018/0310822 A1 11/2018 Indorf et al.
 2018/0310823 A1 11/2018 Al-Ali et al.
 2018/0317826 A1 11/2018 Muhsin et al.
 2019/0015023 A1 1/2019 Monfre
 2019/0117070 A1 4/2019 Muhsin et al.
 2019/0200941 A1 7/2019 Chandran et al.
 2019/0239787 A1 8/2019 Pauley et al.
 2019/0320906 A1 10/2019 Olsen
 2019/0374139 A1 12/2019 Kiani et al.
 2019/0374173 A1 12/2019 Kiani et al.
 2019/0374713 A1 12/2019 Kiani et al.
 2020/0060869 A1 2/2020 Telfort et al.
 2020/0111552 A1 4/2020 Ahmed
 2020/0113435 A1 4/2020 Muhsin
 2020/0113488 A1 4/2020 Al-Ali et al.
 2020/0113496 A1 4/2020 Scruggs et al.
 2020/0113497 A1 4/2020 Triman et al.
 2020/0113520 A1 4/2020 Abdul-Hafiz et al.
 2020/0138288 A1 5/2020 Al-Ali et al.
 2020/0138368 A1 5/2020 Kiani et al.
 2020/0163597 A1 5/2020 Dalvi et al.
 2020/0196877 A1 6/2020 Vo et al.
 2020/0253474 A1 8/2020 Muhsin et al.
 2020/0253544 A1 8/2020 Belur Nagaraj et al.
 2020/0275841 A1 9/2020 Telfort et al.
 2020/0288983 A1 9/2020 Telfort et al.
 2020/0321793 A1 10/2020 Al-Ali et al.
 2020/0329983 A1 10/2020 Al-Ali et al.
 2020/0329984 A1 10/2020 Al-Ali et al.
 2020/0329993 A1 10/2020 Al-Ali et al.
 2020/0330037 A1 10/2020 Al-Ali et al.
 2021/0022628 A1 1/2021 Telfort et al.
 2021/0104173 A1 4/2021 Pauley et al.
 2021/0113121 A1 4/2021 Diab et al.
 2021/0117525 A1 4/2021 Kiani et al.
 2021/0118581 A1 4/2021 Kiani et al.
 2021/0121582 A1 4/2021 Krishnamani et al.
 2021/0161465 A1 6/2021 Barker et al.
 2021/0236729 A1 8/2021 Kiani et al.
 2021/0256267 A1 8/2021 Ranasinghe et al.
 2021/0256835 A1 8/2021 Ranasinghe et al.
 2021/0275101 A1 9/2021 Vo et al.
 2021/0290060 A1 9/2021 Ahmed
 2021/0290072 A1 9/2021 Forrest
 2021/0290080 A1 9/2021 Ahmed
 2021/0290120 A1 9/2021 Al-Ali
 2021/0290177 A1 9/2021 Novak, Jr.
 2021/0290184 A1 9/2021 Ahmed

2021/0296008 A1 9/2021 Novak, Jr.
 2021/0330228 A1 10/2021 Olsen et al.
 2021/0386382 A1 12/2021 Olsen et al.

FOREIGN PATENT DOCUMENTS

EP 0659058 1/1999
 EP 1207536 5/2002
 GB 2358546 11/1999
 JP 6214898 1/1987
 JP 01-309872 6/1998
 JP 10-155755 6/1998
 JP 2001-50713 5/1999
 JP 2001-321347 11/2001
 JP 2002-028138 1/2002
 JP 2003-329719 11/2003
 JP 2006-516000 6/2006
 WO WO 1994/005207 3/1994
 WO WO 1994/013207 6/1994
 WO WO 1995/029632 11/1995
 WO WO 1999/053277 10/1999
 WO WO 2000/010462 3/2000
 WO WO 2001/034033 5/2001
 WO WO 2001/078059 10/2001
 WO WO 2001/097691 12/2001
 WO WO 2002/003042 1/2002
 WO WO 2003/058646 7/2003
 WO WO 2003/087737 10/2003
 WO WO 2004/000111 12/2003
 WO WO 2004/004411 1/2004
 WO WO 2004/034898 4/2004
 WO WO 2005/096922 10/2005
 WO WO 2005/096931 10/2005
 WO WO 2005/099562 10/2005
 WO WO 2006/097866 9/2006
 WO WO 2008/017246 2/2008
 WO WO 2008/080469 7/2008
 WO WO 2008/148172 12/2008
 WO WO 2009/093159 7/2009
 WO WO 2009/137524 11/2009

OTHER PUBLICATIONS

US 9,579,050 B2, 02/2017, Al-Ali (withdrawn)
 Cannesson et al., "Relation Between Respiratory Variations in Pulse Oximetry Plethysmographic Waveform Amplitude and Arterial Pulse Pressure in Ventilated Patients", *Critical Care* 2005, Aug. 23, 2005, pp. R562-R568.
 GE Healthcare, "Transport Pro™ Patient Monitor Operator's Manual" Apr. 9, 2007, in 286 pages.
 Hsu, "Signals and Systems", *Schaum's Theory and Problems*, 1995, Ch. 3, p. 121.
 Szecsei, "Homework Helpers Basic Math and Pre-Algebra", 2006, The Career Press, p. 133.
 Analog Devices, 12-Bit Serial Input Multiplying D/A Converter, Product Data Sheet, 2000.
 Chambrin, M-C.; "Alarms in the intensive care unit: how can the number of false alarms be reduced?"; *Critical Care* Aug. 2001, vol. 5 No. 4; p. 1 -5.
 Eldor et al., "A device for monitoring ventilation during anaesthesia; the paratracheal audible respiratory monitor", *Canadian Journal of Anaesthesia*, 1990, vol. 9, No. 1, p. 95-98.
 Gorges, M. et al.; "Improving Alarm Performance in the Medical Intensive Care Unit Using Delays and Clinical Context"; *Technology, Computing, and Simulation*; vol. 108, No. 5, May 2009; p. 1546-1552.
 Imhoff, M et al.; "Alarm Algorithms in Critical Care Monitoring"; *Anesth Analg* 2006;102:1525-37.
 International Search Report & Written Opinion, PCT Application PCT/US2010/052758, dated Feb. 10, 2011; 12 pages.
 International Search Report & Written Opinion, PCT Application PCT/US2010/058981, dated Feb. 17, 2011; 11 pages.
 International Search Report and Written Opinion issued in application No. PCT/US2010/052756 dated Feb. 6, 2012.

(56)

References Cited

OTHER PUBLICATIONS

International Search Report, PCT Application PCT/CA2003/000536, dated Dec. 11, 2003; 2 pages.

International Search Report, PCT Application PCT/US2009/069287, dated Mar. 30, 2010; 7 pages.

Japanese Office Action for JP Application No. 2007-506626 dated Mar. 1, 2011.

Sierra et al., Monitoring Respiratory Rate Based on Tracheal Sounds. First Experiences, Proceedings of the 26th Annual Int'l Conf. of the IEEE EMBS (Sep. 2004), 317-320.

Watt, R. C.; "Alarms and Anesthesia. Challenges in the design of Intelligent systems for Patient Monitoring"; IEEE Engineering in Medicine and biology; Dec. 1993, p. 34-41.

Welch Allyn, ECG ASIC, Product Data Sheet, 2001.

Supplementary Partial European Search Report for International Application No. 05732095.4, dated Jun. 26, 2009 in 4 pages.

Theimer et al., "Definitions of audio features for music content description", Algorithm Engineering Report TR08-2-001, Feb. 2008.

Stewart, C., Larson, V., "Detection and classification of acoustic signals from fixed-wing aircraft," Systems Engineering, CH3051-0/91/0000-0025, IEEE, 1991.

Johnston, Development of a Signal Processing Library for Extraction of SpO₂, HR, HRV, and RR from Photoplethysmographic Waveforms, Thesis: Degree of Master of Science, Worcester Polytechnic Institute, date of presentation/defense Jul. 17, 2006, date listed Jul. 27, 2006.

* cited by examiner




FIG. 1




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4A




FIG. 4B




FIG. 4C

FIG. 4D




FIG. 5A




FIG. 5B




FIG. 5C

FIG. 5D




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 8D

FIG. 8C




FIG. 9




FIG. 10

FIG. 11A




FIG. 11B




FIG. 11C





FIG. 11D







FIG. 12



V	VI
1_1	11_
_11	⋮
	16_
	21_
	⋮
	26_
	31
	⋮
	66_

FIG. 13




FIG. 14




FIG. 15A




FIG. 15B




FIG. 16




FIG. 17

PLETHYSMOGRAPHIC RESPIRATION RATE DETECTION

PRIORITY CLAIM TO RELATED PROVISIONAL APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 15/095,912, filed Apr. 11, 2016, titled Plethysmographic Respiration Rate Detection, which is a divisional of U.S. patent application Ser. No. 13/076,423, filed Mar. 30, 2011, titled Plethysmographic Respiration Processor, which claims priority benefit under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 61/319,256, filed Mar. 30, 2010, titled Plethysmographic Respiration Processor and U.S. Provisional Patent Application No. 61/364,141, filed Jul. 14, 2010, titled Plethysmographic Respiration Detector; all of the above-cited patent applications are hereby incorporated by reference herein.

BACKGROUND OF THE INVENTION

Pulse oximetry is a widely accepted noninvasive procedure for measuring the oxygen saturation level of arterial blood, an indicator of a person's oxygen supply. A typical pulse oximetry system utilizes an optical sensor clipped onto a fingertip to measure the relative volume of oxygenated hemoglobin in pulsatile arterial blood flowing within the fingertip. Oxygen saturation (SpO₂), pulse rate and a plethysmograph waveform, which is a visualization of pulsatile blood flow over time, are displayed on a monitor accordingly.

Conventional pulse oximetry assumes that arterial blood is the only pulsatile blood flow in the measurement site. During patient motion, venous blood also moves, which causes errors in conventional pulse oximetry. Advanced pulse oximetry processes the venous blood signal so as to report true arterial oxygen saturation and pulse rate under conditions of patient movement. Advanced pulse oximetry also functions under conditions of low perfusion (small signal amplitude), intense ambient light (artificial or sunlight) and electrosurgical instrument interference, which are scenarios where conventional pulse oximetry tends to fail.

Advanced pulse oximetry is described in at least U.S. Pat. Nos. 6,770,028; 6,658,276; 6,157,850; 6,002,952; 5,769,785 and 5,758,644, which are assigned to Masimo Corporation ("Masimo") of Irvine, Calif. and are incorporated by reference herein. Corresponding low noise optical sensors are disclosed in at least U.S. Pat. Nos. 6,985,764; 6,813,511; 6,792,300; 6,256,523; 6,088,607; 5,782,757 and 5,638,818, which are also assigned to Masimo and are also incorporated by reference herein. Advanced pulse oximetry systems including Masimo SET® low noise optical sensors and read through motion pulse oximetry monitors for measuring SO₂, pulse rate (PR) and perfusion index (PI) are available from Masimo. Optical sensors include any of Masimo LNOP®, LNCS®, Soffouch™ and Blue™ adhesive or reusable sensors. Pulse oximetry monitors include any of Masimo Rad-8®, Rad-5®, Rad®-5v or SatShare® monitors.

Advanced blood parameter measurement systems are described in at least U.S. Pat. No. 7,647,083, filed Mar. 1, 2006, titled Multiple Wavelength Sensor Equalization; U.S. patent application Ser. No. 11/367,036, filed Mar. 1, 2006, titled Configurable Physiological Measurement System; U.S. patent application Ser. No. 11/367,034, filed Mar. 1, 2006, titled Physiological Parameter Confidence Measure and U.S. patent application Ser. No. 11/366,208, filed Mar. 1, 2006, titled Noninvasive Multi-Parameter Patient Moni-

tor, all assigned to Masimo Laboratories, Irvine, Calif. (Masimo Labs) and all incorporated by reference herein. Advanced blood parameter measurement systems include Masimo Rainbow® SET, which provides measurements in addition to SO₂, such as total hemoglobin (SpHb™), oxygen content (SpOC™), methemoglobin (SpMet®), carboxyhemoglobin (SpCO®) and PVI®. Advanced blood parameter sensors include Masimo Rainbow® adhesive, ReSposable™ and reusable sensors. Advanced blood parameter monitors include Masimo Radical-7™, Rad-87™ and Rad-57™ monitors, all available from Masimo. Such advanced pulse oximeters, low noise sensors and advanced blood parameter systems have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.

SUMMARY OF THE INVENTION

Advantageously, a plethysmographic respiration processor provides respiration rate readings based upon optical properties of pulsatile blood flow. The respiration rate so derived may be used alone or combined with respiration rate derived by various other means including, but not limited to, microphones or other acoustic sensors located to respond to various body sounds; humidity sensors located to respond to inhalation/exhalation moisture; thermistors and photodiodes located to respond to inhalation/exhalation air temperature; capacitance sensors located to respond to inhalation/exhalation air pressure; and venturi effect sensors located to respond to inhalation/exhalation air flow. In a particularly advantageous embodiment, a plethysmographic respiration detector is used in conjunction with an acoustic monitor or combined blood parameter and acoustic monitor, such as a Masimo Rainbow® SET platform and an acoustic respiration rate (RRa™) sensor available from Masimo, so as to improve the accuracy of, robustness of, or otherwise supplement acoustic-derived respiration rate measurements or other acoustic-derived respiration parameters.

One aspect of a plethysmographic respiration processor is responsive to respiration affecting blood volume and a corresponding detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of respiration rate. The plethysmographic respiration detector comprises a preprocessor, processors and decision logic. The preprocessor identifies a windowed pleth corresponding to a physiologically acceptable series of plethysmograph waveform pulses. The processors derive various spectrums of the windowed pleth. Each of the processors is configured so that its corresponding spectrum is particularly responsive to a specific respiratory effect on the windowed pleth. The decision logic determines a respiration rate based upon matching features of at least two of the spectrums.

In various embodiments, the processors comprise a baseline processor that inputs the windowed pleth and outputs a "baseline" spectrum. The baseline processor has a first signal conditioner and a first frequency transform. The first signal conditioner generates a first conditioned pleth from the windowed pleth. The first frequency transform inputs the first conditioned pleth and generates the baseline spectrum.

The processors further comprise an amplitude modulation (AM) processor that inputs the windowed pleth and outputs an "AM" spectrum. The AM processor has a second signal conditioner that generates a second conditioned pleth from the windowed pleth. A demodulator AM demodulates the second conditioned pleth to generate a demodulated pleth. A

second frequency transform inputs the demodulated pleth and generates the AM spectrum.

The processors further comprise a shape modulation (SM) processor that inputs the windowed pleth and outputs a "SM" spectrum. The SM processor has a third signal conditioner that generates a third conditioned pleth from the windowed pleth. A feature extractor generates a modulated metric from the third conditioned pleth. A third frequency transform generates the SM spectrum from the modulated metric.

The decision logic has a peak detector, a comparator and a respiration rate output. The peak detector operates on at least two of the baseline spectrum, the AM spectrum and the SM spectrum so as to determine local maximums. The comparator determines if there are any local maximums from the at least two of the spectrums that occur at matching frequencies within a predetermined tolerance. A respiration rate output is generated if the comparator finds at least a two-way match. A smoother operates on multiple respiration rate outputs derived over a sliding series of the windowed pleths so as to derive a smoothed respiration rate output. A tested condition rejects the respiration rate output if it differs from the smoothed respiration rate output by more than a predetermined amount.

Another aspect of a respiration rate processor is inputting a plethysmograph waveform, determining a baseline spectrum responsive to a respiratory-induced baseline shift of the plethysmograph waveform, determining an amplitude modulation (AM) spectrum responsive to a respiratory-induced amplitude modulation of the plethysmograph waveform, determining a shape modulation (SM) spectrum responsive to a respiratory-induced shape modulation of the plethysmograph waveform, and matching at least two of the baseline, AM and SM spectrums so as to derive a respiration rate. In an embodiment, determining a baseline spectrum comprises frequency transforming the plethysmograph waveform. In an embodiment, determining an AM spectrum comprises demodulating the plethysmograph waveform so as to generate a demodulated pleth; and frequency transforming the demodulated pleth. In an embodiment, determining a SM spectrum comprises feature extracting the plethysmograph waveform so as to generate a modulated metric and frequency transforming the modulated metric.

In various other embodiments, matching comprises detecting peaks in at least two of the spectrums, comparing the detected peaks so as to find one peak from each of the at least two spectrums occurring at a particular frequency and outputting the particular frequency as the respiration rate. Windowed pleths are defined by a sliding window of acceptable portions of the plethysmograph waveform. The respiration rate output is smoothed based upon a median respiration rate calculated over multiple ones of the windowed pleths. The particular frequency is rejected if it is not within a predetermined difference of the smoothed respiration rate.

A further aspect of a respiration rate processor is a baseline processor, an AM processor, a SM processor and decision logic. The baseline processor identifies a respiration-induced baseline shift in a plethysmograph waveform. The AM processor identifies a respiration-induced amplitude modulation of the plethysmograph waveform. The SM processor identifies a respiration-induced shape modulation of the plethysmograph waveform. The decision logic compares the respiration-induced baseline shift, amplitude modulation and shape modulation so as to derive a respiration rate.

In various embodiments, the baseline processor generates a baseline spectrum from a first frequency transform of the plethysmograph waveform. The AM processor generates an AM spectrum from a second frequency transform of demodulated plethysmograph waveform. The SM processor generates an SM spectrum from a third frequency transform of a modulated metric extracted from the plethysmograph waveform. Decision logic has a peak detector and a comparator. The peak detector determines local maximums in each of the baseline spectrum, AM spectrum and SM spectrum. In an embodiment, the comparator determines a three-way match in the frequency of the local maximums in the spectrums. In an embodiment, the comparator determines a two-way match in the frequency of the local maximums in the spectrums, and a condition for accepting the two-way match compares a respiration rate determined by the two-way match to a smoothed respiration rate.

A further aspect of a plethysmographic respiration processor is responsive to respiratory modulation of a blood volume waveform or corresponding detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of a respiration parameter. A demodulator processes a sensor signal so as to generate a plethysmograph waveform. A pulse processor identifies candidate pulses from the plethysmograph waveform. A pulse modeler identifies physiologically acceptable ones of the candidate pulses. The plethysmographic respiration processor has a feature extractor, a normalizer and a feature analyzer. The feature extractor processes the acceptable pulses so as to calculate pulse features. The normalizer compares the pulse features so as to calculate a pulse parameter. The feature analyzer calculates a respiration parameter from the pulse parameter.

In various embodiments, the pulse features comprise a difference (E) between an acceptable pulse and a triangular pulse estimate; the pulse features comprise an area (A) under a triangular pulse; or the pulse features are calculated with respect to a diastolic (d) portion of an acceptable pulse and a corresponding diastolic portion of a triangular pulse. In various embodiments, the normalizer compares a diastolic difference (Ed) with a diastolic area (Ad) or the normalizer calculates Ed/Ad. In an embodiment, the feature analyzer determines the frequency spectrum of Ed/Ad so as to determine a respiration rate.

Yet another aspect of a plethysmographic respiration processor detects a tissue site response to optical radiation having a plurality of wavelengths, demodulates the response according to wavelength so as to generate a corresponding plurality of plethysmograph waveforms, identifies acceptable pulses from at least one of the waveforms and calculates a respiration parameter from the acceptable pulses. To calculate a respiration parameter, in various embodiments the processor estimates an acceptable pulse with a triangular pulse and determines a systolic portion and a diastolic portion of the acceptable pulse and the triangular pulse; compares the triangular to the acceptable pulse so as to define pulse features; normalizes the pulse features according to the systolic and diastolic portions so as to generate a pulse parameter; or analyzes the pulse parameter to derive a respiration parameter. The comparing may comprise differencing the acceptable pulse and the triangular pulse over the diastolic portion. The analyzing may comprise transforming the pulse parameter to a frequency parameter and outputting a respiration rate according to a maximum of the frequency parameter.

Additional aspects of plethysmographic respiration processor has a pulse input having physiologically acceptable

5

pleth pulses derived from a plethysmograph waveform. A feature extractor extracts pulse features from the pulse input. The pulse features are modulated by respiration. A normalizer calculates a pulse parameter from the relative magnitude of a first one of the pulse features compared with a second one of the pulse features. A feature analyzer calculates a respiration parameter from the pulse parameter.

In various embodiments, the feature extractor may calculate a difference between a triangular pulse estimate and a corresponding pleth pulse. The feature may also calculate an area under a portion of the triangular pulses. The processor may differentiate between a systolic pulse feature and a diastolic pulse feature. The feature extractor may calculate an apex angle of the slope portion of a triangular pulse estimate. The feature analyzer may perform a frequency transform to extract a respiration rate from the pulse parameter.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a block diagram of a plethysmographic respiration processor embodiment;

FIGS. 2A-B are a block diagram of a pre-processor embodiment and a time illustration of a sliding window, respectively;

FIGS. 3A-C are a block diagram of a baseline processor, an intensity versus time graph of a baseline modulated pleth, and a baseline frequency spectrum, respectively;

FIGS. 4A-D are a block diagram of an AM processor, an intensity versus time graph of an AM pleth, and AM pleth frequency spectrum and a demodulated pleth frequency spectrum, respectively;

FIGS. 5A-D are a block diagram of an SM processor, an intensity versus time graph of an SM pleth, and graph of a shape metric versus time; and a shape metric frequency spectrum, respectively;

FIGS. 6A-B are intensity versus time graphs of a shape modulated pulse illustrating area-based shape metrics;

FIGS. 7A-B are intensity versus time graphs of a shape modulated pulse illustrating arc-length shape metrics;

FIG. 8A-D are a block diagram of an FM processor, an intensity versus time graph of an FM pleth, and graph of a dicrotic-notch based FM metric versus time; and a FM metric frequency spectrum, respectively;

FIG. 9 is a block diagram of a pre-processor embodiment;

FIG. 10 is a block diagram of a plethysmographic respiration processor embodiment;

FIGS. 11A-D are a spectrums of a combined baseline shifted and AM modulated pleth; a spectrum of a demodulated baseline shifted and AM modulated pleth; a SM spectrum; and a non-idealized spectrum, respectively;

FIG. 12 is a decision logic flowchart for advantageously deriving a robust value for respiration rate based upon a baseline, an AM and a SM processor operating on an acceptable window of pleths; and

FIG. 13 is a decision logic flowchart for advantageously deriving a robust value for respiration rate based upon a baseline, an AM and a high pass filtered (HPF) SM processor operating on an acceptable window of pleths.

FIG. 14 is a perspective view of a non-invasive physiological parameter measurement system having a monitor and a corresponding optical sensor and incorporating a plethysmographic respiration processor;

FIGS. 15A-B are graphs of light absorption profiles for pulsatile blood perfused tissue and surrounding tissue and an optical sensor detected light intensity, respectively;

6

FIG. 16 is block diagram of a non-invasive physiological parameter measurement system having a monitor and a corresponding optical sensor and incorporating a plethysmographic respiration processor; and

FIG. 17 is a block diagram of a modulated plethysmograph demodulator.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

FIG. 1 illustrates a plethysmographic respiration processor 100 embodiment having a plethysmograph waveform (pleth) input 101 and a respiration rate (RR) output 104. The pleth respiration processor 100 includes a preprocessor 200, one or more pleth processors 120 and a post processor 130. The pleth 101 is derived from an optical sensor attached to a tissue site, which is in communications with a pulse oximeter or blood parameter monitor, as described with respect to FIGS. 14-17, below. The pre-processor 200 derives acceptable pleths 112, as described in detail with respect to FIGS. 2A-B, below. The pleth processor(s) 120 each operate on acceptable pleths 112 so as to generate respiration-rated parameters 102 responsive to a person's respiration. The pleth processors 120 may operate in the time domain, the frequency domain or a mix of time or frequency domains. Pleth processors 120 are described in detail with respect to FIGS. 3-8, below. The post-processor 130 resolves or otherwise verifies the respiration-related parameters 102 so as to derive a respiration rate and, perhaps, averages, smoothes or otherwise filters that respiration rate so as to generate the respiration rate (RR) 104 output. Advantageously, this optical sensor derived RR may be used to derive a less intrusive measure of respiration rate or used in combination with acoustic, mechanical, electrical, temperature or other sensors and monitors so as to determine a more accurate or robust measure of respiration rate. Although described herein as deriving a respiration rate, a plethysmographic respiration processor 100 output may be similarly expressed as a respiration or a breathing frequency or interval, among others.

FIGS. 2A-B illustrate a pre-processor 200 having a pleth 101 input and generating a conditioned pleth 112, as described below. The pre-processor 200 has a candidate pulse processor 220, a pulse modeler 230, a sliding window 240, a pleth windower 250 and a signal conditioner 260. A single pleth channel is selected from a multiple demodulated pleths 1705 (FIG. 17) as a representative pleth 101 input. In an embodiment, the representative pleth channel corresponds to the IR wavelength channel of a (two wavelength) pulse oximeter.

As shown in FIG. 2A, the pleth 101 is fed into a candidate pulse processor 220 that removes noise and artifacts and identifies the start and end of pulses that conform to various tests of physiological acceptability. In an embodiment, the candidate pulse processor 220 has curvature, low-pass filter and edge finder components that remove waveform features that do not correspond to the steep inflow phase during ventricular systole or the longer outflow phase during diastole, including the characteristic dichrotic notch and miscellaneous waveform curvature changes. Accordingly, the candidate pulse processor 220 identifies "edges" within an input waveform segment that connect a peak and subsequent valley of a pleth pulse. The candidate pulse processor 220 also has delta T, zero crossing, amplitude threshold and slope checks so as to eliminate certain of the edges that were identified by the curvature, filter and edge finder components that do not meet certain conditions. The delta T

discards all the edges that are either too slow or too quick to be physiological. The zero crossing check eliminates all edges that do not cross the zero line, such as small bumps that are not peaks or valleys. The amplitude threshold check removes larger “bumps” than the zero crossing check, such as dirotic notches. The slope check is based on the observation that in a physiological pulse, the ventricular contraction, i.e. descending pulse portion, is steeper than any subsequent trend in the ascending pulse portion. The pulse finder transforms the edges remaining after the various edge checks into candidate pulses **222**, which are fed into the pulse modeler **230**.

Also shown in FIG. 2A, the pulse modeler **230** takes the candidate pulses **222** and identifies which of these are acceptable pulses **232**, which satisfy an internal model for a physiological plethysmographic waveform. Although the candidate pulse processor **220** performs a series of checks on edges, the pulse modeler **230** performs a series of checks on pulse features. The first component of the pulse modeler calculates relevant pulse features. The remainder of the pulse modeler checks these pulse features to identify physiologically acceptable features. The pulse features component extracts three items of information about the input candidate pulses that are needed for downstream processing by the other components of the pulse modeler including pulse starting point, period and signal strength. The downstream components include a max BPM check, a stick model check, an angle check, a ratio check and a signal strength check. The maximum beats-per-minute (max BPM) check discards pulses having a period that is below a minimum number of samples. The stick model check discards pulses where the corresponding waveform does not fit a stick model. The angle check is based on computing the angle of a normalized slope for the ascending portion of a pulse so as to discard pulses that are extremely asymmetric. The ratio check removes pulses in which the ratio between the duration of the ascending pulse portion and the duration of the descending pulse portion is less than a certain threshold. The signal strength check assigns a confidence value to each pulse, based on its signal strength, and low confidence pulses are discarded. A pulse processor **220** and a pulse modeler **230** are described in U.S. Pat. No. 6,463,311 titled Plethysmograph Pulse Recognition Processor, issued Oct. 8, 2002, assigned to Masimo Corporation and incorporated by reference herein.

Further shown in FIGS. 2A-B, the sliding window **240** defines a series of fixed-time-length (T) samples (“windows”) of pleth, where each window **242** is shifted from the previous window by a fixed time interval (Δt) **244**. In an embodiment, each window is $T=2125$ samples (34 sec) in length at 16 msec per sample (62.5 Hz sample rate), where successive windows are shifted by $\Delta t=2$ sec. Each window is either accepted **242** or rejected **248** as designated by an acceptable window **242** output. The pleth windower **250** utilizes the acceptable windows **242** designation to accept a corresponding section of the “raw” pleth **101** input and generate a windowed (raw) pleth **252** output. That is, the pre-processor **200** advantageously allows downstream processing to operate directly on the demodulated pleth while discarding those raw pleth sections that are deemed unacceptable, based upon various pleth models and checks as described above. In an embodiment, the signal conditioner **260** demeans/detrends and bandpass filters the windowed pleth **252** to generate a conditioned pleth **112** output. In an embodiment, the bandpass filter is an IIR filter having a 12-240 bpm (beats per minute) passband. In another embodiment described below with respect to FIG. 9, below,

a pre-processor **200** generates windowed features from acceptable pulses derived from the pleth **101** input.

FIGS. 3A-B illustrate a baseline processor **300** that derives a “baseline” spectrum F_b **302** responsive to a respiration-induced baseline shift in a pleth. As shown in FIG. 3A, the baseline processor **300** has a conditioned pleth **301** input and generates a corresponding baseline spectrum F_b **302**. As shown in FIG. 3B, the conditioned pleth **301** has a pleth period **381** inversely related to pulse rate (PR). Under certain conditions, an individual’s respiration induces a cyclical shift in the pleth baseline **382**. The cyclical shift period **383** is inversely related to respiration rate (RR). As shown in FIG. 3C, a frequency spectrum **302** of the baseline-shifted pleth **301** includes a relatively large pulse rate (PR) peak **392** and a relatively small respiration rate (RR) peak **391**.

In other embodiments, a baseline processor **300** employs a time domain calculation of the conditioned pleth **301** that determines the period **383** of a cyclical baseline shift and hence respiration rate. Such a time domain calculation may be based upon envelope detection of the conditioned pleths **301**, such as a curve-fit to the peaks (or valleys) of the pleth pulses. Measurements of a cyclical variation in a plethysmograph baseline are described in U.S. patent application Ser. No. 11/221,411 titled Noninvasive Hypovolemia Monitor, filed Sep. 6, 2005 and published as US 2006/0058691 A1, assigned to Masimo and incorporated by reference herein.

FIGS. 4A-B illustrate an AM processor **400** that derives an “AM” spectrum F_{am} **402** responsive to a respiration-induced amplitude modulation of the pleth. As shown in FIG. 4A, the AM processor **400** has a conditioned pleth **401** input and generates a corresponding AM spectrum F_{am} **402** that is responsive to a demodulated pleth **422**. In an embodiment, the demodulator **420** squares, low pass filters (LPF) and square-roots the conditioned pleth **401** to generate a demodulated pleth **422**. In an embodiment, the frequency transformation **430** utilizes a Hamming window, a chirp-Z FFT algorithm and a magnitude calculation so as to generate an AM spectrum **402** for the demodulated pleth **422**.

As shown in FIG. 4B, a pleth **401** has a pleth period **471** inversely related to pulse rate (PR). Under certain conditions, an individual’s respiration amplitude modulates (AM) **472** the plethysmograph **401**. In particular, the modulation period **473** is inversely related to respiration rate (RR). As shown in FIG. 4C, a spectrum **480** of the pleth **401** includes a pulse rate (PR) peak **481** and respiration sidebands **482**, **483** displaced by RR on either side of the PR peak **481**. As shown in FIG. 4D a spectrum **402** of the demodulated pleth **422** includes a DC peak **491** resulting from the demodulated pulse rate “carrier” translated to DC and a respiration rate (RR) peak **492** resulting from the demodulated sidebands **482**, **483**.

An AM processor **400** is described above as demodulating **420** a conditioned pleth **401**. In other embodiments, a time domain calculation of the conditioned pleth **401** determines the respiration modulation period **473** and hence the respiration rate. That time domain calculation may be based upon envelope detection of the conditioned pleth **401**, such as a curve-fit to the peaks (or valleys) of the plethysmograph or, alternatively, the peak-to-peak variation. Measurements of variation in a plethysmograph envelope are described in U.S. patent application Ser. No. 11/952,940 titled Plethysmograph Variability Processor, filed Dec. 7, 2007 and published as US 2008/0188760 A1, assigned to Masimo and incorporated by reference herein.

FIGS. 5A-D illustrate a shape modulation (SM) processor 500 that derives an “SM” spectrum F_s 502 responsive to a respiration-induced shape modulation of the pleth. As shown in FIG. 5A, the SM processor 500 has a conditioned pleth 501 input and generates a corresponding SM spectrum F_s 502. In an embodiment, the SM processor 500 includes a feature extractor 520, a high pass filter (HPF) 530 and a frequency transform 540. In another embodiment, the SM processor includes the feature extractor 520 and a frequency transform 540, but excludes the high pass filter 530. The feature extractor 520 generates a shape-based modulated metric 522, such as E/A described below. In an embodiment, the HPF 530 is a time domain difference filter that calculates $Y_{n+1}-Y_n$ so as to remove an erroneous first (low frequency) peak in the SM spectrum F_s 502. In an embodiment, the frequency transformation 540 utilizes a Hamming window, a chirp-Z FFT algorithm and a magnitude calculation so as to generate the SM spectrum 502 for each windowed conditioned pleth 501.

As shown in FIG. 5B, a pleth 501 has a pleth period 571 inversely related to pulse rate (PR). Under some circumstances, an individual’s respiration modulates the shape of each pleth pulse. This modulation may be described in terms of a predefined pleth feature or “shape metric.” In an advantageous embodiment, a shape metric is defined by a difference or “error” E 572 between the diastolic portion of a pleth pulse and its corresponding triangular pulse approximation, normalized by the area A 573 under the triangular pulse approximation.

As shown in FIG. 5C, a respiration-modulated shape metric 522 has a cyclical period 581 inversely related to respiration rate (RR). As shown in FIG. 5D, a spectrum 502 of the modulated shape metric 522 includes a respiration rate (RR) peak 591.

A SM processor 500 is described above as based upon a normalized diastolic error metric (E/A). In other embodiments, shape metrics may be based upon other pulse features such as a diastolic area, error or angle normalized by the corresponding systolic area, error or angle (Ad/As, Ed/Es, $\theta d/\theta s$), or shape metrics may be related to the arc length of the diastolic and/or systolic portions of a pleth pulse, to name a few. These and other pulse shapes and features responsive to respiration are also contemplated herein.

FIGS. 6A-B further illustrates pulse shape features that are derived by a feature extractor 520 (FIG. 5A) embodiment. Acceptable pleth pulses 610 are generated by the pre-processor 200 (FIG. 2A), as described above. For convenience of illustration, the inverse of an “intensity” pulse is shown, as described with respect to FIGS. 15A-B, below. The pleth pulse 610 has a peak Y at a time Wand corresponding valleys at times X and Z. The peak and valleys define a triangular pulse 620 XYZ that approximates the pleth pulse 610. Further, the time line WY corresponding to the peak Y divides the pleth pulse 610 into a systolic portion 630 and a diastolic portion 640.

As shown in FIG. 6A, a systolic error Es 631 is defined as the total area between the pleth pulse 610 and the approximate triangular pulse 620 within the systolic portion 630. A diastolic error Ed 641 is defined as the total area between the pleth pulse 610 and the triangular pulse 620 within the diastolic portion 640.

As shown in FIG. 6B, a systolic area As 632 is defined as the total area under the triangular pulse 620 within the systolic portion 630. A diastolic area Ad 642 is defined as the total area under the triangular pulse 620 within the diastolic portion 640. A systolic angle θs 633 is defined as the angle XYW defined by the triangular pulse within the systolic

portion 630. A diastolic angle θd 643 is defined as the angle ZYW defined by the triangular pulse within the diastolic portion 640.

Based upon the above-described pulse feature definitions, normalized pulse features may be defined. These may include normalized diastolic pulse features, such as Ed/Ad, corresponding to the diastolic triangular pulse error normalized by the diastolic triangular pulse area. Other normalized diastolic pulse features may include a diastolic area, error or angle normalized by the corresponding systolic area, error or angle (Ad/As, Ed/Es, $\theta d/\theta s$).

FIGS. 7A-B illustrate additional pulse shape features. As shown in FIG. 7A, pulse features may be based upon the length of a curve (trace, arc, path or line) portion of a pleth pulse 710. In particular, a diastolic curve length Ld 745 between the pulse peak Y and valley Z is defined in polar coordinates as:

$$Ld = \int_Y^Z \sqrt{r^2 + \left(\frac{dr}{d\theta}\right)^2} d\theta \quad (\text{EQ. 1})$$

where r is the distance from W (time corresponding to the peak Y) to any point V along the curve 710 and θ is the angle between r and the time axis WZ. Ld 745 may be similarly defined in Cartesian coordinates. A systolic curve length Ls 735 may be defined in similar fashion. A normalized length pulse feature Ld/Ls may be defined accordingly. In other embodiments, pulse features Ld 745 or Ls 735 may be normalized by the diastolic 640 or systolic 630 areas or angles defined with respect to FIG. 6B, above. In various embodiments, pulse features Ld 745 or Ls 735 also may be normalized by pulse height WY, by diastolic WZ or systolic XW pulse widths, by total pulse width XZ or by mathematical combinations of these measures of pulse height and pulse width to name a few.

As shown in FIG. 7B, pulse shape features may be based upon the curvature of a portion of a pleth pulse 710. In particular, a curvature κ is defined in pedal coordinates as:

$$\kappa = \frac{1}{r} \frac{dp}{dr} \quad (\text{EQ. 2})$$

where the pedal coordinates of a point V with respect to the pulse 710 and the pedal point W are the radial distance r from W to V and the perpendicular distance p from W to the line t tangent to the pulse 710 at V, as shown. κ may be similarly defined in Cartesian or polar coordinates. Total curvature K of a curve segment between points a and b is then

$$K = \int_a^b \kappa(s) ds \quad (\text{EQ. 3})$$

A diastolic curvature Kd 746 or systolic curvature Ks 736 pulse shape feature may be defined accordingly. In other embodiments, a curvature pulse shape feature may be defined according to the absolute value of the maximum and/or minimum curvature of the pulse 710 or pulse segment 730, 740, or the curvature of a particular feature, such as a diastolic notch. In other embodiments, pulse shape features Kd 746 or Ks 736 may be normalized by the diastolic 640 or systolic 630 areas or angles defined above with respect to

11

FIGS. 6A-B. In various embodiments, pulse features **Kd 746** or **Ks 736** also may be normalized by pulse height **WY**, by diastolic **WZ** or systolic **XW** pulse widths, by total pulse width **XZ** or by mathematical combinations of these measures of pulse height and pulse width to name a few. In other embodiments, various normalized systolic and/or diastolic pulse features may be similarly defined.

FIG. 8A-D illustrate an FM processor **800** that derives an “FM” spectrum F_{fm} **802** responsive to a respiration-induced frequency modulation of the pleth. As shown in FIG. 8A, the FM processor **800** has a conditioned pleth **112** input and generates a corresponding FM spectrum F_{fm} **802** that is responsive to a demodulated pleth **822**. In an embodiment, the demodulator **820** utilizes a metric Δ responsive to the time difference between identifiable epochs of each pleth pulse. In an embodiment, the epochs are based upon a dicrotic notch. In an embodiment, the metric Δ is the time difference between two identifiable portions of a dicrotic notch such as the notch local maximum, local minimum, or mid-point between local maximum and local minimum, to name a few.

As shown in FIG. 8B, a pleth **801** has a pleth period **871** inversely related to pulse rate (PR). Under certain conditions, an individual’s respiration frequency modulates (FM) the plethysmograph **801**. In particular, the modulation period **881** (FIG. 8C) is inversely related to respiration rate (RR). FIG. 8C illustrates a respiration-modulated FM metric **822** over time. In particular, an FM metric **822**, such as the metric Δ described above, has a cyclical period **881** inversely related to respiration rate (RR). As shown in FIG. 8D, a spectrum **802** of the FM metric **822** includes a respiration rate (RR) peak **891**.

FIG. 9 illustrates another pre-processor **900** embodiment having a pleth **101** input and generating a windowed features **962** output. The pre-processor **900** has a candidate pulse processor **220** and pulse modeler **230** that operate on the pleth **101** input so as to generate an acceptable pulses **232** output, as described with respect to FIG. 2A, above. Further, the pre-processor **900** has a time base standard **940**, a feature extractor/normalizer **950**, and a windowing/outlier rejecter **960**. The time base standard **940** inputs acceptable pulses **941** and outputs resized pulses **942**. In particular, the time base standard **940** mathematically re-samples the input pulses **941** so that each pulse has the same number of samples. For example, if a standard pulse has 50 samples and an input pulse **941** has 60 samples, then the input pulse **941** sample interval is made larger by 60/50 or 1.2 times so that the resized input pulse width is 50 samples. Similarly, if an input pulse **941** has 40 samples, then the input pulse **941** sample interval is made smaller by 40/50 or 0.8 times so that the resized input pulse width is 50 samples. A resized input pulse is derived by interpolating the original pulse at re-sampled points. For example, a linear interpolation embodiment is used according to the following

$$y = \left(\frac{y_2 - y_1}{x_2 - x_1} \right) (x - x_1) + y_1 \quad (\text{EQ. 4})$$

where $X_2 - X_1$ is the original sample interval; Y_1 and Y_2 are input pulse **401** values at X_1 and X_2 , respectively; x is a resized sample point between X_1 and X_2 and y is the resized pulse value at x . In other embodiments, the interpolation is a cubic spline or a polynomial interpolation to name a few.

Also shown in FIG. 9, the feature extractor/normalizer **950** inputs the resized pulses **942** described above and

12

outputs normalized pulse features **952**. Pulse features may include one or more of the differences or “errors” E between an acceptable pulse and its corresponding triangular pulse; areas A under the triangular pulse; and apex angles θ of a triangular pulse, to name a few, as described in detail with respect to FIGS. 6-7, above. Pulse features may also distinguish between a steeper-slope portion corresponding to systole S and a shallower-slope portion corresponding to diastole D . Pulse features are normalized by comparing one or more extracted features with one or more other extracted features. In an embodiment, normalized pulse features **952** advantageously include E_d/A_d corresponding to the diastolic triangular pulse error normalized by the diastolic triangular pulse area. Other normalized pulse features **952** may include a diastolic area, error or angle normalized by the corresponding systolic area, error or angle (A_d/A_s , E_d/E_s , θ_d/θ_s). These and additional normalized pulse features relating to an acceptable pulse and/or its corresponding triangular pulse are also contemplated herein and described with respect to FIGS. 6-7, above.

Further shown in FIG. 9, the windowing/outlier rejecter **960** inputs the normalized features **952** and outputs windowed features **962**. The windowed features **962**, in turn, may be frequency transformed or analyzed in the time domain to determine a respiration modulation of the features, as described above. In particular, windowing **960** defines a sample size (window size) of the normalized features **952**. The outlier rejecter **960** calculates a mean or median of the normalized features **952** falling within the window, defines an acceptable range around the mean or median and rejects normalized features falling outside of that acceptable range.

Window size may be a function of a respiration rate (RR) **964**, a heart rate (HR) **966** or both. In particular, HR **966** corresponds to the input pulse **101** frequency and hence determines the time between samples of the normalized features **952**. RR **964** corresponds to the number of feature cycles within a window and hence sets a lower limit on the window size in order to resolve the frequency of those feature cycles.

Pulse rates may typically vary from a resting rate of 40-60 BPM for athletes to 60-90 BPM for non-athletes. Maximum heart rates are typically defined as $220 - \text{age}$. Hence, pulse rates might typically range from 50 to 200 BPM, which is a 4:1 variation in time between samples (0.3 sec to 1.2 sec). Respiration rates may typically vary between 12-20 breaths per minute for resting adults to 35-45 breaths per minute for exercising adults. Hence RR may typically range from 10-50 breaths per minute, which is a 5:1 variation in the number of respiration cycles per window. Accordingly, the number of pulse feature samples per respiration cycle may have a 20:1 variation.

Windowing **960** may be fixed or adjustable. Further, successive windows may be overlapping, i.e. a sliding window may be used, or may be adjacent and non-overlapping. A typical window size may range, say, between 15-120 sec. or more. Accordingly, a window size may encompass, say, 20 respiration cycles at 10 breaths per minute over a 120 sec. window to 12 respiration cycles at 50 breaths per minute over a 15 sec. window. In an embodiment, the window size is adaptively adjusted based upon detected RR and PR.

FIG. 10 illustrates a plethysmographic respiration processor **1000** embodiment having a conditioned plethysmograph waveform (pleth) **112** input and a smoothed respiration rate (RRs) **1005** output. The respiration processor **1000** includes parallel processors **1020**, decision logic **1100-1300** and a smoother **1030**. The conditioned pleth **112** contains pleth

sections corresponding to sliding acceptable windows designated by the pre-processor 200 (FIG. 2A), as described above with respect to FIGS. 2A-B. The parallel processors 1020 each operate on conditioned pleth 112 so as to generate frequency spectrums 1022 responsive to respiration rate. The parallel processors 1020 include a baseline processor 300, an amplitude modulation (AM) processor 400, a high pass filtered (HPF) shape modulation (SM) processor 500 and a SM processor 501. In particular, the baseline processor 300 derives a “baseline” spectrum F_b 302 responsive to a respiration-induced baseline shift in a pleth. The baseline processor 300 is described in detail with respect to FIGS. 3A-C, above. The AM processor 400 derives an “AM” spectrum F_{am} 402 responsive to a respiration-induced amplitude modulation of the pleth. The AM processor 400 is described in detail with respect to FIGS. 4A-D, above. The SM processors 500, 501 derive “SM” spectrums F_s 502, F_s' 504 each responsive to a respiration-induced shape modulation of the pleth. The SM processors 500, 501 are described in detail with respect to FIGS. 5-7, above.

As described above, the processors 1020 each generate one spectrum 1022 for each sliding window of the conditioned pleth 112. Accordingly, the decision logic 1100-1300 attempts to generate a respiration rate (RR) value for each conditioned pleth 112 window. The decision logic 1100-1300 compares two or more of the spectrums F_b , F_{am} , F_s and F_s' 422 so as to calculate a respiration rate (RR) 1004. If the decision logic 1100-1300 cannot determine a RR 1004 value from the spectrums 1022, the corresponding conditioned pleth window 112, is rejected. A smoother 1030 generates a smoothed respiration rate 1005 calculated over multiple respiration rate 1004 values. In an embodiment, the smoother 1030 determines the median value of RR 1004 corresponding to multiple ones of the conditioned pleth windows 112. In an embodiment, the median value is calculated over five conditioned pleth windows 112. The decision logic 1100-1300 is described in detail with respect to FIGS. 11-13, below.

FIGS. 11A-C illustrate the output of the baseline processor 300 (FIG. 10), AM processor 400 (FIG. 10) and SM processor 500 (FIG. 10), respectively, assuming that a conditioned pleth 112 (FIG. 10) exhibits each of a baseline shift, an amplitude modulation and a shape modulation due to respiration. As shown in FIG. 11A, in view of both a respiration-induced baseline shift and AM modulation, the windowed pleth spectrum 1110 is a combination of a baseline shift spectrum 302 (FIG. 3C) and an AM spectrum 402 (FIG. 4D). This combination is also the baseline spectrum F_b 302 (FIG. 3A), i.e. the frequency transform of the conditioned pleth 112. Hence, in this example, the baseline spectrum 1110 has two possible local maximums or “peaks” 1115, 1116. One peak is due to respiration shifting the pleth baseline and one peak is due to respiration amplitude modulating the pleth. However, these peaks cannot be distinguished. In particular, if $RR < 0.5 PR$, then peak 1115 is at a frequency corresponding to RR and peak 1116 is at a frequency corresponding to $PR-RR$. Likewise, if $RR > 0.5 PR$, then peak 1115 is at a frequency corresponding to $PR-RR$ and peak 1116 is at a frequency corresponding to RR. That is, “twin” peaks 1115, 1116 occur symmetrically on either side of frequency $\frac{1}{2} PR$, one at frequency RR and one at frequency $PR-RR$, but the peak corresponding to the respiration rate RR cannot be resolved by the baseline processor 302 (FIG. 10) alone.

As shown in FIG. 11B, in view of both a respiration-induced baseline shift and AM modulation, the AM spectrum F_{am} 402 (FIG. 10) is a combination of the spectrums of

FIG. 3C and FIG. 4C after demodulation. Hence, in this example, the AM processor output 402 (FIG. 10) has two possible local maximums or peaks 1125, 1126. One peak is due to demodulating the pleth corresponding to the spectrum of FIG. 4C, resulting in the spectrum of FIG. 4D. The other peak is due to demodulating the pleth corresponding to the spectrum of FIG. 3C, which translates the pleth fundamental 392 (FIG. 3C) at PR to DC and the respiration-related peak 391 (FIG. 3C) to $PR-RR$. As with the peaks described with respect to FIG. 11A, these “twin” peaks 1125, 1126 occur symmetrically on either side of $\frac{1}{2} PR$, but the peak corresponding to the respiration rate RR cannot be resolved by the AM processor 400 (FIG. 10) alone.

As shown in FIG. 11C, the SM spectrum F_s 502 is unaffected by either a baseline shift or by amplitude modulation. In particular, a respiration-induced baseline shift, which shifts the entire pleth waveform up or down, has negligible effect on the error E 572 (FIG. 5B) or the triangular area A 573 (FIG. 5B). Further, although respiration-induced AM increases or decreases the pleth amplitude, this is accounted for by normalizing the error E by the triangular area A. As such, in view of both a respiration-induced baseline shift and AM, the SM spectrum F_s 502 is responsive only to shape modulation, as shown in FIG. 5D, i.e. a single local maximum or peak 1135 occurs at the respiration rate.

As shown in FIGS. 11A-C, ideally respiration rate may be determined by first verifying the existence of twin peaks 1115, 1116 symmetric about 0.5 PR in the baseline spectrum 1110 and twin peaks about 0.5 PR in the AM spectrum 1120. Second, one twin from each spectrum 1110, 1120 is matched with the single peak in the SM spectrum 1130. For example, a match between peaks 1115 (FIG. 11A), 1125 (FIG. 11B) and 1135 (FIG. 11C) would provide a robust indication of RR. However, pleths from various sensors, monitors and patients may yield spectrums with erroneous peaks due to physiological conditions or artifact. Accordingly, various peaks and matching conditions are utilized by the decision logic to determine RR, as described with respect to FIGS. 12-13, below.

As shown in FIG. 11D, a peak identifying nomenclature 1140 is used in describing decision logic with respect to the baseline spectrum F_b 302 (FIG. 10) and the AM spectrum F_{am} 402 (FIG. 10). The largest peak in a spectrum is designated ① and its twin designated ④. If the largest peak is the first peak, which is sometimes erroneous, then the second largest peak is designated ② and its twin designated ⑤. If the largest peak is the last peak, which is also sometimes erroneous, the second largest peak is designated ③ and its twin designated ⑥.

FIG. 12 illustrates the decision logic 1200 for advantageously deriving a robust value for respiration rate based upon each of the baseline 300, AM 400 and SM 500 processors (FIG. 10) operating on a conditioned pleth 112 (FIG. 10). The spectrums F_b , F_{am} and F_s from these processors are input 1210 into the decision logic 1200. A peak detector 1220 locates the largest peak ① and its twin ④ from each of F_b 1110 (FIG. 11A) and F_{am} 1120 (FIG. 11B) and the largest peak ① from F_s 1130 (FIG. 11C). The comparator 1230 looks for a three-way match from, say, the largest peak from each of the spectrums. This comparison is denoted 1-1-1, designating the largest peaks from the spectrums F_b - F_{am} - F_s , respectively. If the frequencies of all of these peaks match 1240, within a predetermined error, then that frequency is output as the respiration rate 1250 for that conditioned pleth window 112 (FIG. 10). If there is no match 1240, other combinations 1260, 1266 of peaks of a particular

series are compared **1230**, such as the largest peak from F_b , the twin to the largest peak from F_{am} and the largest peak from F_s , denoted 1-4-1. Hence, all of the following combinations are denoted the first series of combinations to try, i.e. series I: 1-1-1; 1-4-1; 4-1-1; 4-4-1.

As shown in FIG. **12**, if there are no matches from series I, other series **1270**, **1275** having different types of combinations are tried, as explained below. If a particular twin cannot be located, the corresponding series is rejected **1275**. If no 3-way matching peaks are found after trying all combinations in each of series I, II, III, IV **1270**, then that particular window is rejected **1280** and no respiration rate value is determined that corresponds to that window.

Series II represents a second set of peak comparisons. In some cases, the largest peak ① from F_b or F_{am} or both may be the first peak, which is often erroneous. As such, comparisons may be made using the second largest peaks ② from F_b and F_{am} and the corresponding twins ⑤. The twins in this series are verified to exist, but not used. Accordingly, in an embodiment, the largest peaks ① and the second largest peaks ② are compared in the following combinations: 2-1-1; 1-2-1; 2-2-1.

Series III represents a third set of peak comparisons. In some cases, the largest peak from F_b or F_{am} or both may be the last peak, which is also often erroneous. As such, comparisons may be made using the second largest peaks ③ from F_b and F_{am} and the corresponding twins ⑥. Accordingly, in an embodiment, these peaks are compared in the following combinations: 3-3-1; 6-3-1; 3-6-1; 6-6-1.

Series IV represents yet another set of peak comparisons. In some cases, the largest peak from F_s is erroneous. Hence, comparisons may be made using the largest peak from F_s' , designated ③, and the largest peak and corresponding twin from F_b and F_{am} , designated ① and ④, as noted above. Accordingly, in an embodiment, these peaks are compared with each other in the following combinations: 4-4-3; 4-1-3; 1-4-3; 1-1-3. In other embodiments, other combinations are possible, for example, the twins to the second largest peaks from F_b and F_{am} , which are designated ⑤, could be used in various combinations with other designated peaks described above. If all combinations fail to yield a three-way match **1240**, then that particular window is rejected **1280**.

FIG. **13** illustrates decision logic **1300** for advantageously deriving a robust value for respiration rate based upon a two-way match of the spectrums F_b , F_{am} and F_s (or F_s') from each of the baseline **300**, AM **400** and shape **500**, **501** processors (FIG. **10**) plus an additional condition **1390**. In an embodiment, decision logic **1300** is used in the event a respiration rate RR **1004** (FIG. **10**) cannot be derived from a three-way match of the spectrums F_b , F_{am} and F_s (or F_s'), as described with respect to FIG. **12**, above.

As shown in FIG. **13**, in a series V, the largest peaks from F_b and F_s , denoted 1_1 (without utilizing F_{am}) are compared for a two-way match **1330**. If there is a match, an additional condition **1370** must be met. In an embodiment, the condition **1390** is that the matching frequencies of F_b and F_s must be within a predetermined difference of the smoothed respiration rate (RRs) **1005** (FIG. **10**). In an embodiment, the predetermined difference is 1 bpm. If so, the matching frequencies are output as the respiration rate RR **1380**. If not, the largest peaks from F_{am} and F_s , denoted _11 (without utilizing F_b) are also compared for a match **1330**. If there is a match from this comparison and the additional condition **1370** is met, then the matching frequencies are output as the respiration rate RR **1380**. If these combinations are compared without a match **1350**, then a series VI is utilized.

Also shown in FIG. **13**, in a series VI, the various peaks from F_b and F_{am} , each denote 1-6, are compared for a two-way match **1330**. If there is a match, the additional condition **1370** must be met. If all combinations, e.g. 11, 12, 13 . . . 21, 22, 23 . . . 36, 46, 56 are tried without a match or there is a match but the additional condition is not met, the window is rejected **1360**. In other embodiments, other peaks are compared **1330** and other conditions **1390** must be met.

FIG. **14** illustrates a physiological monitoring system **1400** that incorporates a plethysmographic respiration processor **100** (FIG. **1**), as described above. The monitoring system **1400** has a monitor **1410**, an optical sensor **1420** and an interconnect cable **1430** connecting the monitor **1410** and sensor **1420**. The monitoring system **1400** generates physiological parameters that indicate one or more aspects of a person's physical condition, including, advantageously, a plethysmograph-derived respiration rate. The sensor **1420** attaches to a tissue site **10**, such as a fingertip, and is capable of irradiating the tissue site **10** with differing wavelengths of light and detecting the light after attenuation by pulsatile blood flow within the tissue site **10**. The monitor **1410** communicates with the sensor **1420** via the interconnect cable **1430** to receive one or more detected intensity signals and to derive from those intensity signals one or more physiological parameters. The monitor also has a display **1413** for presenting parameter values, including respiration rate (RR). Controls **1415** set alarm limits, processing modes, display formats and more. An audio transducer **1416** provides alarm sounds, pulse beeps and button press feedback to name a few. Indicators **1418** show monitor status. The display **1413** may include readouts, colored lights or graphics generated by LEOs, LCOs or CRTs to name a few and is capable of displaying indicia representative of calculated physiological parameters, including respiration rate, and waveforms, including plethysmographs. The display **1413** is also capable of showing historical or trending data related to one or more of the measured parameters or combinations of the measured parameters. User I/O may include, for example, push buttons **1415** and indicators **1418**. The push buttons may be soft keys with display-indicated functions or dedicated function keys **1415**. Other user I/O (not shown) may include keypads, touch screens, pointing devices, voice recognition devices and the like.

FIG. **15A** illustrates a light absorption waveform **1501** at an illuminated peripheral tissue site corresponding to a pulsatile blood volume at that site. The peripheral tissue site is illuminated by, and the corresponding absorption is (indirectly) measured by, an optical sensor **1420** (FIG. **14**), as described above. A y-axis **1530** represents the total amount of light absorbed by the tissue site, with time shown along an x-axis **1540**. The total absorption is represented by layers, including the static absorption layers due to tissue **1532**, venous blood **1534** and a baseline of arterial blood **1536**. Also shown is a variable absorption layer **1538** due to the pulse-added volume of arterial blood that is used to derive a plethysmograph, as described above and further with respect to FIG. **15B**, below. This light absorption waveform **1501** varies as a function of the wavelength of the optical sensor emitted light according to the blood constituency. Indeed, it is this wavelength variation that allows a multi-parameter patient monitor to determine blood hemoglobin components and other blood constituents along with respiration rate characteristics, as described above.

As shown in FIG. **15A**, a pulsatile blood volume **1538** is a function of heart stroke volume, pressure gradient, arterial elasticity and peripheral resistance. The ideal pulsatile blood

volume waveform displays a broad peripheral flow curve, with a short, steep inflow phase **1516** followed by a 3 to 4 times longer outflow phase **1518**. The inflow phase **1516** is the result of tissue distention by the rapid blood volume inflow during ventricular systole. During the outflow phase **1518**, blood flow continues into the vascular bed during diastole. The end diastolic baseline **1514** indicates the minimum basal tissue perfusion. During the outflow phase **1518** is a dicrotic notch **1515**. Classically, the dicrotic notch **1515** is attributed to closure of the aortic valve at the end of ventricular systole. However, it is also a function of reflection from the periphery of an initial, fast propagating pressure pulse that occurs upon the opening of the aortic valve preceding the arterial flow wave. Pulsatile blood volume varies with physiological properties such as heart stroke, vessel size, elasticity and vascularization, to name a few. Accordingly, the blood flow waveform shape can vary significantly from individual to individual and between tissue sites.

FIG. **15B** illustrates a plethysmograph waveform **1502** detected by an optical sensor **1420** (FIG. **14**). In particular, detected intensity is shown along the y-axis **1550** versus time shown along the x-axis **1560**. The plethysmograph waveform **1502** is a time series of plethysmograph (“pleth”) pulses and relates to the time-varying pulsatile blood volume **1538** (FIG. **15A**) measured at a particular location on a person, referred to herein as a “tissue site.” A tissue site can be a fingertip, ear lobe, toe, nose or forehead to name just a few. A person is used herein as the referenced subject of optical sensor measurements, but other living species also have a measurable pleth and are included within the scope of this disclosure.

As shown in FIG. **15B**, an optical sensor **1420** (FIG. **14**) does not directly detect absorption and, hence, does not directly measure the volume waveform **1538** (FIG. **15A**). However, the plethysmograph waveform **1502** is merely an out-of-phase version of the volume profile **1538**. Stated differently, the plethysmograph waveform **1502** varies inversely with the pulsatile blood volume **1538**. In particular, the peak detected intensity **1554** occurs at minimum volume **1514** and the minimum detected intensity **1552** occurs at maximum volume **1512**. Further, a rapid rise in volume during the inflow phase **1516** is reflected in a rapid decline in intensity **1556**; and the gradual decline in volume during the outflow phase **1518** is reflected in a gradual increase **1558** in detected intensity. The intensity waveform **1502** also displays a dicrotic notch **1555**.

FIG. **16** further illustrates a physiological monitoring system **1600** having an optical sensor **1620** attached to a tissue site **10**, a monitor **1610** and an interconnecting sensor cable **1620**. The sensor **1620** has emitters **1622**, each of which transmit light of a specified wavelength. Drivers **1654**, **1655** convert digital control signals into analog drive signals capable of activating the emitters **1622**. A front-end **1652**, **1653** converts composite analog intensity signal(s) from the detector(s) **1624** into digital data input to a digital signal processor (DSP) **1658**. The DSP **1658** may comprise any of a wide variety of data and/or signal processors capable of executing programs for determining physiological parameters from input data. In an embodiment, the DSP executes firmware **1659** including pre-processors, respiration processors and post processors, such as described with respect to FIGS. **1-13**, above.

Also shown in FIG. **16**, an instrument manager **1682** may comprise one or more microcontrollers controlling system management, such as monitoring the activity of the DSP **1658**. The instrument manager **1682** has an interface port

1683 for monitor communications. In an embodiment, the interface port **1683** has a display driver, an audio driver, user inputs and I/O for driving displays and alarms, responding to buttons and keypads and providing external device input/output communications. In an embodiment, the displays can indicate a variety of physiological parameters **1686** such as respiration rate (RR), pulse rate (PR), plethysmograph (pleth), perfusion index (PI), pleth variability index (PVI), signal quality (IQ) and values for blood constituents including oxygen saturation (SpO₂), carboxyhemoglobin (HbCO), methemoglobin (HbMet), total hemoglobin (Hbt) and oxygen content (OC) as well as instrument and sensor status, such as sensor life, to name but a few.

FIG. **17** illustrates a demodulator **1700** having a modulated/multiplexed detector signal **1703** input and demodulated signal **1705** outputs. That is, the demodulator input **1703** is the result of a detector **1624** (FIG. **16**) response to N emitter wavelengths **1622** (FIG. **16**) that are cyclically turned on and off by emitter drivers **1654** (FIG. **16**) so as to illuminate a tissue site with multiple wavelength optical radiation, as is well known in the pulse oximetry art. The digitized detector signal **1703** corresponds to the A/D converter **1657** (FIG. **16**) input to the DSP **1658** (FIG. **16**). The DSP has demodulator **1700** (preprocessor) firmware **1659** which generates N channels of demodulated signals $r_1(t)$, $r_2(t)$, . . . , $r_N(t)$ **1705** in response. One signal $r_i(t)$ corresponding to each emitter wavelength **1622**. These demodulated signals are plethysmographs, as described above.

The demodulator **1700** has mixers **1730** and low pass filters **1740** for each channel and demodulating signals $d_i(t)$ **1704** provided to each mixer **1730**. The demodulating signals are linear combinations of (orthogonal) basis functions of the form

$$d_i(t) = \sum_{j=1}^M \beta_{ij} \cdot \phi_j(t) \quad (\text{EQ. 5})$$

which are derived by approximating the optical response of the emitters to on/off periods of the emitter drivers. M is the number of basis functions needed to approximate such optical responses. $\phi_j(t)$ is the j^{th} basis function used by the demodulator. In one embodiment, the basis functions are of the form

$$\phi_j(t) = \sin\left(\frac{2\pi}{T} jt + b_j \frac{\pi}{2}\right); b_j \in [0, 1] \quad (\text{EQ. 6})$$

where T is the period of the repeating on/off patterns of the emitter drivers. Accordingly, the lowpass filter outputs **1705** are $r_1(t)$, $r_2(t)$, . . . , $r_N(t)$, which are estimates of absorption for each emitter wavelength in view of noise $n(t)$ that is additive to each channel. Plethysmograph demodulators are described in U.S. Pat. No. 5,919,134 titled Method and Apparatus for Demodulating Signals in a Pulse Oximetry System, issued Jul. 6, 1999; U.S. Pat. No. 7,003,338 titled Method and Apparatus for Reducing Coupling Between Signals, issued Feb. 21, 2006; and U.S. patent application Ser. No. 13/037,321 titled Plethysmograph Filter, filed Feb. 28, 2011; all assigned to Masimo Corporation and incorporated by reference herein.

Advantageously, a plethysmographic respiration processor **100** (FIG. **1**) is implemented on an advanced pulse oximetry monitor or an advanced blood parameter monitor,

as described above. Although a plethysmographic respiration processor is described above with respect to deriving respiration rate from a plethysmograph waveform, in other embodiments, a plethysmographic respiration processor may be used to derive other respiration-related parameters. In a particularly advantageous embodiment, a plethysmographic respiration processor is used in conjunction with an acoustic monitor or combined blood parameter and acoustic monitor so as to improve the accuracy of, robustness of, or otherwise supplement acoustic-derived respiration rate measurements or other acoustic-derived respiration parameters.

A plethysmographic respiration processor has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims herein. One of ordinary skill in art will appreciate many variations and modifications.

What is claimed is:

1. A patient monitor configured to determine a respiration rate from a plethysmograph waveform, the patient monitor comprising:

a preprocessor configured to receive a plethysmograph waveform from a noninvasive sensor monitoring a patient and identify a plurality of portions of the plethysmograph waveform which include physiologically acceptable series of plethysmograph waveform pulses; and

one or more processors configured to:

derive a first set of frequencies from a first respiratory-induced modulation in a portion of the plurality of portions,

derive a second set of frequencies from a second respiratory-induced modulation in the portion, the second respiratory-induced modulation being different from the first respiratory-induced modulation,

compare the first set of frequencies and the second set of frequencies to determine whether any of the first set of frequencies matches any of the second set of frequencies within a tolerance,

generate and output a respiration rate in real time to a display from determining that one of the first set of frequencies matches one of the second set of frequencies within the tolerance, and

activate an alarm in real time if the respiration rate satisfies an alarm threshold.

2. The patient monitor of claim 1, wherein the one or more processors is configured to compare the first set of frequencies and the second set of frequencies until at least determining that none of at least two of the first set of frequencies match none of at least two of the second set of frequencies within the tolerance.

3. The patient monitor of claim 1, wherein the one or more processors is configured to compare the first set of frequencies and the second set of frequencies by comparing individual frequencies of the first set of frequencies and individual frequencies of the second set of frequencies in an order that depends on a pulse rate for the patient.

4. The patient monitor of claim 1, wherein the one or more processors is configured to:

derive a third set of frequencies from a third respiratory-induced modulation in the portion, the third respiratory-induced modulation being different from the first respiratory-induced modulation and the second respiratory-induced modulation;

compare the first set of frequencies, the second set of frequencies, and the third set of frequencies to determine whether any of the first set of frequencies matches

any of the second set of frequencies and any of the third set of frequencies within the tolerance; and
generate and output the respiration rate in real time to the display from determining that the one of the first set of frequencies matches the one of the second set of frequencies and one of the third set of frequencies within the tolerance.

5. The patient monitor of claim 1, wherein the portion comprises plethysmograph data captured from monitoring the patient over a period less than 120 seconds.

6. The patient monitor of claim 1, wherein the one or more processors is configured to:

derive a third set of frequencies from the first respiratory-induced modulation in another portion of the plurality of portions;

derive a fourth set of frequencies from the second respiratory-induced modulation in the another portion;

compare the third set of frequencies and the fourth set of frequencies to determine whether any of the third set of frequencies matches any of the fourth set of frequencies within the tolerance;

generate another respiration rate from determining that one of the third set of frequencies matches one of the fourth set of frequencies within the tolerance; and

derive a combined respiration rate from the respiratory rate and the another respiratory rate.

7. The patient monitor of claim 6, wherein the one or more processors is configured to:

derive a fifth set of frequencies from the first respiratory-induced modulation in yet another portion of the plurality of portions;

derive a sixth set of frequencies from the second respiratory-induced modulation in the yet another portion;

compare the fifth set of frequencies and the sixth set of frequencies to determine whether any of the fifth set of frequencies matches any of the sixth set of frequencies within the tolerance;

generate yet another respiration rate from determining that one of the fifth set of frequencies matches one of the sixth set of frequencies within the tolerance;

determine that the yet another respiration rate differs from the combined respiration rate by more than an amount; and

reject the yet another respiration rate in response to determining that the yet another respiration rate differs from the combined respiration rate by more than the amount.

8. The patient monitor of claim 6, wherein the portion comprises plethysmograph data captured from monitoring the patient over a different period than the another portion.

9. The patient monitor of claim 1, wherein the one or more processors is configured to generate and output the respiration rate in real time to the display from determining that the one of the first set of frequencies matches the one of the second set of frequencies within the tolerance and from determining that an additional condition is met.

10. The patient monitor of claim 9, wherein the additional condition is met when the respiration rate differs from a value by less than an amount.

11. The patient monitor of claim 1, wherein the first respiratory-induced modulation comprises a respiratory-induced baseline shift of the portion, and the second respiratory-induced modulation comprises a respiratory-induced amplitude modulation of the portion.

12. The patient monitor of claim 1, wherein the first respiratory-induced modulation comprises a respiratory-induced baseline shift of the portion, and the second respira-

tory-induced modulation comprises a respiratory-induced shape modulation of the portion.

13. The patient monitor of claim 1, wherein the first respiratory-induced modulation comprises a respiratory-induced amplitude modulation of the portion, and the second 5 respiratory-induced modulation comprises a respiratory-induced shape modulation of the portion.

14. The patient monitor of claim 1, further comprising the display configured to present the respiration rate.

15. The patient monitor of claim 1, wherein the respiration 10 rate comprises the one of the first set of frequencies.

16. The patient monitor of claim 1, further comprising the noninvasive sensor.

* * * * *